Early	O
pro	B-GP
-	I-GP
inflammatory	I-GP
cytokine	I-GP
elevations	O
in	O
the	O
DBA	B-OG
/	I-OG
2J	I-OG
mouse	I-OG
model	O
of	O
glaucoma	B-DS

Background	O

Neuroinflammation	O
—	O
astrogliosis	O
,	O
microglial	O
activation	O
,	O
and	O
changes	O
in	O
cytokine	B-GP
signaling	O
—	O
is	O
a	O
prominent	O
feature	O
of	O
neurodegenerative	B-DS
disorders	I-DS
.	O

Glaucoma	B-DS
is	O
a	O
group	O
of	O
chronic	O
neurodegenerative	O
conditions	O
that	O
make	O
up	O
the	O
leading	O
cause	O
of	O
irreversible	O
blindness	B-DS
worldwide	O
.	O

Neuroinflammation	O
has	O
been	O
postulated	O
to	O
play	O
a	O
significant	O
role	O
in	O
the	O
pathogenesis	O
and	O
progression	O
of	O
glaucomatous	O
neurodegeneration	O
.	O

Though	O
much	O
is	O
known	O
regarding	O
inflammation	O
in	O
the	O
eye	O
in	O
glaucoma	B-DS
,	O
little	O
is	O
known	O
about	O
cytokine	B-GP
activity	O
outside	O
of	O
the	O
retina	O
where	O
pathologies	O
develop	O
early	O
.	O

Methods	O

We	O
traced	O
the	O
primary	O
visual	O
projection	O
from	O
the	O
eye	O
to	O
the	O
superior	O
colliculus	O
(	O
SC	O
)	O
in	O
DBA	O
/	O
2J	O
and	O
DBA	O
/	O
2J	O
.	O
Gpnmb	B-GP
+	O
(	O
control	O
)	O
mice	B-OG
using	O
the	O
anterograde	O
tracer	O
cholera	B-GP
toxin	I-GP
-	I-GP
B	I-GP
(	O
CTB	B-GP
)	O
to	O
assay	O
axonal	O
transport	O
deficits	O
.	O

Forty	O
-	O
eight	O
hours	O
later	O
,	O
visual	O
structures	O
were	O
microdissected	O
from	O
fresh	O
tissue	O
based	O
on	O
transport	O
outcome	O
.	O

Using	O
magnetic	O
bead	O
multiplexing	O
assays	O
,	O
we	O
measured	O
levels	O
of	O
20	O
cytokines	B-GP
in	O
the	O
retina	O
,	O
proximal	O
and	O
distal	O
optic	O
nerves	O
,	O
CTB	B-GP
-	O
positive	O
and	O
negative	O
SC	O
subdivisions	O
,	O
cerebellum	O
,	O
and	O
serum	O
at	O
different	O
ages	O
representing	O
different	O
stages	O
of	O
pathology	O
.	O

Results	O

Pro	O
-	O
and	O
anti	B-GP
-	I-GP
inflammatory	I-GP
cytokine	I-GP
levels	O
in	O
mice	B-OG
often	O
changed	O
in	O
the	O
same	O
direction	O
based	O
on	O
strain	O
,	O
age	O
,	O
and	O
tissue	O
.	O

Significant	O
elevations	O
in	O
retinal	O
pro	B-GP
-	I-GP
inflammatory	I-GP
cytokines	I-GP
were	O
observed	O
in	O
young	O
DBA	B-OG
/	I-OG
2J	I-OG
mice	I-OG
compared	O
to	O
controls	O
,	O
followed	O
by	O
an	O
age	O
-	O
dependent	O
decrease	O
in	O
the	O
DBA	B-OG
/	I-OG
2J	I-OG
mice	I-OG
.	O

Proximal	O
optic	O
nerve	O
of	O
young	O
DBA	B-OG
/	I-OG
2J	I-OG
mice	I-OG
showed	O
a	O
50	O
%	O
or	O
greater	O
decrease	O
in	O
levels	O
of	O
certain	O
cytokines	B-GP
compared	O
to	O
older	O
DBA	O
/	O
2J	O
cohorts	O
and	O
controls	O
,	O
while	O
both	O
proximal	O
and	O
distal	O
optic	O
nerve	O
of	O
DBA	O
/	O
2Js	O
showed	O
elevations	O
in	O
IL	B-GP
-	I-GP
1β	I-GP
at	O
all	O
ages	O
compared	O
to	O
controls	O
.	O

Pro	B-GP
-	I-GP
inflammatory	I-GP
cytokine	I-GP
IL	B-GP
-	I-GP
6	I-GP
levels	O
varied	O
in	O
accordance	O
with	O
transport	O
outcome	O
in	O
the	O
SC	O
:	O
IL	B-GP
-	I-GP
6	I-GP
was	O
elevated	O
44	O
–	O
80	O
%	O
in	O
glaucomatous	O
DBA	O
/	O
2J	O
collicular	O
regions	O
deficient	O
in	O
anterograde	O
transport	O
from	O
retinal	O
ganglion	O
cells	O
(	O
RGCs	O
)	O
compared	O
to	O
areas	O
with	O
intact	O
transport	O
.	O

Conclusion	O

Dysregulation	O
of	O
cytokine	B-GP
signaling	O
in	O
the	O
RGC	O
projection	O
of	O
DBA	B-OG
/	I-OG
2J	I-OG
mice	I-OG
was	O
evident	O
early	O
in	O
distal	O
retinal	O
targets	O
,	O
well	O
before	O
intraocular	O
pressure	O
elevation	O
or	O
axonal	O
degeneration	O
begins	O
.	O

Background	O

Defects	O
in	O
axonal	O
transport	O
have	O
been	O
reported	O
among	O
the	O
earliest	O
pathologies	O
in	O
many	O
neurodegenerative	B-DS
disorders	I-DS
[	O
1	O
,	O
2	O
],	O
including	O
glaucoma	B-DS
[	O
3	O
–	O
6	O
].	O

Anterograde	O
transport	O
deficits	O
have	O
been	O
found	O
to	O
precede	O
retrograde	O
deficits	O
and	O
overt	O
structural	O
degeneration	O
of	O
retinal	O
ganglion	O
cell	O
(	O
RGC	O
)	O
axons	O
[	O
7	O
],	O
indicating	O
that	O
an	O
intact	O
and	O
semi	O
-	O
functional	O
axon	O
persists	O
after	O
initial	O
onset	O
of	O
pathology	O
.	O

Furthermore	O
,	O
astrogliosis	O
occurs	O
in	O
the	O
superior	O
colliculus	O
(	O
SC	O
)	O
after	O
transport	O
deficits	O
but	O
before	O
axon	O
loss	O
[	O
8	O
].	O

Given	O
the	O
early	O
appearances	O
of	O
axon	O
transport	O
deficits	O
and	O
neuroinflammation	O
,	O
obvious	O
questions	O
concern	O
the	O
relationship	O
between	O
these	O
two	O
processes	O
.	O

While	O
much	O
has	O
been	O
reported	O
on	O
inflammation	O
in	O
the	O
retina	O
and	O
optic	O
nerve	O
head	O
,	O
details	O
of	O
immune	B-DS
dysfunction	I-DS
such	O
as	O
changes	O
in	O
cytokine	B-GP
levels	O
have	O
not	O
been	O
examined	O
further	O
along	O
the	O
retinal	O
projection	O
—	O
an	O
area	O
where	O
we	O
first	O
see	O
transport	O
deficits	O
and	O
degeneration	O
[	O
4	O
,	O
9	O
,	O
10	O
].	O

Glaucomatous	O
neurodegeneration	O
is	O
predicted	O
to	O
afflict	O
nearly	O
80	O
million	O
people	O
worldwide	O
by	O
the	O
year	O
2020	O
[	O
11	O
].	O

Age	O
and	O
elevated	O
intraocular	O
pressure	O
(	O
IOP	O
)	O
are	O
major	O
risk	O
factors	O
for	O
glaucoma	B-DS
,	O
with	O
IOP	O
currently	O
comprising	O
the	O
only	O
target	O
of	O
FDA	O
-	O
approved	O
drug	O
treatments	O
.	O

However	O
,	O
what	O
actually	O
blinds	O
in	O
the	O
disease	O
is	O
the	O
dysfunction	O
and	O
degeneration	O
of	O
RGCs	O
[	O
12	O
,	O
13	O
].	O

Also	O
,	O
given	O
the	O
common	O
incidence	O
of	O
elevated	O
IOP	O
without	O
glaucomatous	O
vision	O
loss	O
as	O
well	O
as	O
normal	B-DS
tension	I-DS
glaucoma	I-DS
,	O
it	O
is	O
clear	O
that	O
many	O
other	O
factors	O
play	O
a	O
role	O
in	O
the	O
development	O
and	O
progression	O
of	O
this	O
degenerative	B-DS
disease	I-DS
[	O
14	O
–	O
16	O
].	O

Abnormal	O
activation	O
of	O
the	O
immune	O
system	O
has	O
been	O
shown	O
to	O
produce	O
glaucomatous	O
pathology	O
in	O
the	O
absence	O
of	O
elevated	O
IOP	O
[	O
14	O
].	O

Bosco	O
and	O
colleagues	O
have	O
shown	O
microglial	O
activation	O
within	O
young	O
DBA	B-OG
/	I-OG
2J	I-OG
mouse	I-OG
retina	O
,	O
pre	O
-	O
laminar	O
optic	O
nerve	O
,	O
and	O
nerve	O
head	O
[	O
17	O
,	O
18	O
],	O
which	O
suggests	O
a	O
role	O
for	O
immunomodulatory	O
molecules	O
such	O
as	O
cytokines	B-GP
early	O
in	O
pathology	O
in	O
moderately	O
elevated	O
IOP	O
contexts	O
.	O

At	O
the	O
other	O
extreme	O
,	O
models	O
of	O
high	O
IOP	O
and	O
nerve	O
crush	O
have	O
also	O
demonstrated	O
some	O
reliance	O
on	O
immunomodulation	O
for	O
either	O
protection	O
[	O
19	O
]	O
or	O
propagation	O
of	O
damage	O
[	O
20	O
].	O

Cytokine	B-GP
activity	O
is	O
thought	O
to	O
play	O
a	O
substantial	O
part	O
in	O
anterior	O
chamber	O
changes	O
that	O
can	O
result	O
in	O
elevated	O
IOP	O
[	O
21	O
,	O
22	O
].	O

Interestingly	O
,	O
increased	O
IL	B-GP
-	I-GP
18	I-GP
within	O
anterior	O
chamber	O
structures	O
has	O
been	O
evident	O
even	O
in	O
young	O
DBA	B-OG
/	I-OG
2J	I-OG
mice	I-OG
before	O
they	O
exhibit	O
elevated	O
IOP	O
[	O
21	O
].	O

Additionally	O
,	O
increases	O
in	O
IL	B-GP
-	I-GP
6	I-GP
-	I-GP
type	I-GP
cytokines	I-GP
and	O
members	O
of	O
the	O
JAK	B-GP
-	O
STAT	B-GP
(	O
Janus	B-GP
kinase	I-GP
signal	B-GP
transducer	I-GP
and	I-GP
activator	I-GP
of	I-GP
transcription	I-GP
)	O
signaling	O
pathway	O
were	O
shown	O
in	O
early	O
pressure	O
-	O
induced	O
optic	B-DS
nerve	I-DS
head	I-DS
(	I-DS
ONH	I-DS
)	I-DS
injury	I-DS
[	O
23	O
].	O

Microglial	O
release	O
of	O
IL	B-GP
-	I-GP
6	I-GP
in	O
mixed	O
cultures	O
of	O
RGCs	O
,	O
microglia	O
,	O
and	O
astrocytes	O
in	O
response	O
to	O
hydrostatic	O
pressure	O
illustrates	O
an	O
important	O
link	O
between	O
cytokine	B-GP
levels	O
and	O
risk	O
factors	O
for	O
developing	O
glaucoma	B-DS
[	O
24	O
].	O

Upregulation	O
of	O
genes	O
associated	O
with	O
immune	O
responses	O
(	O
e	O
.	O
g	O
.,	O
Edn2	B-GP
)	O
have	O
been	O
localized	O
to	O
the	O
retina	O
and	O
ONH	O
of	O
DBA	B-OG
/	I-OG
2J	I-OG
mice	I-OG
very	O
early	O
on	O
in	O
this	O
disease	O
model	O
,	O
and	O
therapeutic	O
attempts	O
to	O
block	O
these	O
responses	O
have	O
shown	O
promise	O
in	O
ameliorating	O
glaucomatous	O
pathology	O
[	O
25	O
].	O

Previous	O
characterizations	O
of	O
cytokine	B-GP
levels	O
in	O
the	O
context	O
of	O
glaucoma	B-DS
and	O
related	O
stressors	O
,	O
however	O
,	O
being	O
primarily	O
isolated	O
to	O
portions	O
of	O
the	O
anterior	O
chamber	O
or	O
retina	O
,	O
fail	O
to	O
tell	O
the	O
entire	O
story	O
regarding	O
inflammatory	O
signaling	O
in	O
glaucomatous	O
neurodegeneration	O
.	O

Observations	O
of	O
microglial	O
status	O
within	O
the	O
proximal	O
portion	O
of	O
the	O
RGC	O
projection	O
,	O
in	O
conjunction	O
with	O
cytokine	B-GP
measurements	O
in	O
the	O
eye	O
,	O
suggest	O
that	O
inflammatory	O
signaling	O
may	O
be	O
an	O
early	O
and	O
ubiquitous	O
dysfunction	O
that	O
appears	O
prior	O
to	O
clinically	O
diagnosable	O
vision	O
loss	O
.	O

Therefore	O
,	O
it	O
would	O
be	O
beneficial	O
to	O
assess	O
cytokine	B-GP
levels	O
throughout	O
the	O
entire	O
RGC	O
projection	O
,	O
especially	O
given	O
the	O
observation	O
of	O
anterograde	O
transport	O
deficits	O
and	O
distal	B-DS
axonopathy	I-DS
in	O
glaucoma	B-DS
[	O
4	O
].	O

Furthermore	O
,	O
elucidating	O
any	O
relationship	O
between	O
cytokine	B-GP
levels	O
and	O
axonal	O
transport	O
outcome	O
to	O
the	O
SC	O
is	O
important	O
in	O
moving	O
towards	O
a	O
clinically	O
relevant	O
means	O
of	O
preventing	O
,	O
halting	O
,	O
or	O
treating	O
the	O
disease	O
.	O

If	O
changes	O
in	O
cytokine	B-GP
signaling	O
do	O
occur	O
within	O
the	O
RGC	O
projection	O
prior	O
to	O
transport	O
loss	O
and	O
RGC	O
death	O
,	O
such	O
findings	O
could	O
open	O
the	O
door	O
for	O
potential	O
therapies	O
that	O
focus	O
on	O
restoring	O
and	O
maintaining	O
function	O
rather	O
than	O
replacing	O
lost	O
structure	O
or	O
treating	O
risk	O
factors	O
,	O
such	O
as	O
IOP	O
,	O
in	O
lieu	O
of	O
the	O
actual	O
mechanisms	O
that	O
drive	O
vision	O
loss	O
.	O

Methods	O

Animals	B-OG

Mixed	O
-	O
sex	O
DBA	O
/	O
2J	O
(	O
n	O
=	O
32	O
;	O
10	O
–	O
12	O
per	O
age	O
group	O
)	O
and	O
DBA	O
/	O
2J	O
-	O
Gpnmb	B-GP
+	O
(	O
n	O
=	O
14	O
;	O
6	O
–	O
8	O
per	O
group	O
)	O
mice	B-OG
of	O
different	O
ages	O
were	O
used	O
for	O
these	O
studies	O
(	O
refer	O
to	O
Table	O
1	O
for	O
specific	O
group	O
nomenclature	O
and	O
group	O
n	O
values	O
).	O

The	O
DBA	B-OG
/	I-OG
2J	I-OG
mouse	I-OG
has	O
two	O
loss	O
of	O
function	O
mutations	O
that	O
produce	O
iris	B-DS
atrophy	I-DS
resulting	O
in	O
age	O
-	O
related	O
elevation	O
of	O
IOP	O
and	O
progressive	O
degeneration	O
of	O
visual	O
structures	O
that	O
mimic	O
human	B-OG
glaucoma	B-DS
[	O
26	O
].	O

DBA	O
/	O
2J	O
-	O
Gpnmb	B-GP
+	O
mice	B-OG
(	O
D2G	O
)	O
have	O
the	O
same	O
background	O
as	O
DBA	B-OG
/	I-OG
2J	I-OG
mice	I-OG
;	O
however	O
,	O
they	O
express	O
a	O
functioning	O
wild	O
-	O
type	O
Gpnmb	B-GP
+	O
allele	O
that	O
prevents	O
them	O
from	O
developing	O
elevated	O
IOP	O
or	O
glaucomatous	O
pathology	O
[	O
27	O
].	O

All	O
animals	B-OG
were	O
originally	O
obtained	O
from	O
The	O
Jackson	O
Laboratory	O
(	O
Bar	O
Harbor	O
,	O
ME	O
,	O
USA	O
)	O
and	O
were	O
then	O
housed	O
and	O
aged	O
in	O
the	O
Comparative	O
Medicine	O
Unit	O
at	O
Northeast	O
Ohio	O
Medical	O
University	O
.	O

As	O
the	O
DBA	O
/	O
2J	O
model	O
has	O
shown	O
pathological	O
variability	O
in	O
the	O
literature	O
,	O
we	O
based	O
our	O
age	O
groups	O
for	O
comparison	O
on	O
previous	O
work	O
published	O
by	O
ours	O
and	O
other	O
lab	O
groups	O
[	O
4	O
,	O
7	O
,	O
8	O
,	O
28	O
]	O
and	O
included	O
the	O
following	O
:	O
3	O
–	O
5	O
-	O
month	O
-	O
old	O
mice	B-OG
(	O
D3	O
–	O
5	O
)	O
representing	O
pre	O
-	O
glaucomatous	O
ages	O
,	O
8	O
–	O
10	O
-	O
month	O
-	O
old	O
mice	B-OG
(	O
D8	O
–	O
10	O
)	O
representing	O
early	O
glaucomatous	O
pathology	O
where	O
anterograde	O
transport	O
deficits	O
and	O
mild	O
axonopathy	B-DS
are	O
evident	O
,	O
and	O
12	O
–	O
15	O
-	O
month	O
-	O
old	O
mice	B-OG
(	O
D12	O
–	O
15	O
)	O
representing	O
increasing	O
transport	O
deficits	O
and	O
axonopathy	B-DS
characteristic	O
of	O
late	O
glaucomatous	O
pathology	O
[	O
4	O
,	O
7	O
,	O
8	O
,	O
28	O
].	O

For	O
controls	O
,	O
we	O
used	O
3	O
–	O
5	O
-	O
month	O
-	O
and	O
12	O
–	O
15	O
-	O
old	O
D2G	O
mice	B-OG
to	O
represent	O
ages	O
targeted	O
for	O
pre	O
-	O
glaucomatous	O
and	O
late	O
glaucomatous	O
time	O
points	O
(	O
G3	O
–	O
5	O
and	O
G12	O
–	O
15	O
,	O
respectively	O
).	O

Staging	O
of	O
glaucomatous	O
mice	B-OG
was	O
based	O
on	O
previous	O
work	O
from	O
our	O
lab	O
as	O
well	O
as	O
others	O
(	O
refer	O
to	O
[	O
4	O
,	O
7	O
,	O
28	O
])	O
and	O
was	O
based	O
on	O
the	O
loss	O
of	O
anterograde	O
and	O
retrograde	O
transport	O
and	O
eventual	O
RGC	O
loss	O
.	O

We	O
examined	O
all	O
retinas	O
before	O
tissue	O
preparation	O
to	O
determine	O
that	O
our	O
tracer	O
injections	O
succeeded	O
and	O
we	O
did	O
not	O
see	O
large	O
-	O
scale	O
loss	O
of	O
RGCs	O
or	O
diminished	O
uptake	O
of	O
CTB	B-GP
(	O
Fig	O
.	O
1	O
).	O

All	O
mice	B-OG
were	O
maintained	O
in	O
the	O
same	O
housing	O
unit	O
under	O
a	O
12	O
-	O
h	O
light	O
/	O
dark	O
cycle	O
with	O
standard	O
rodent	O
chow	O
available	O
ad	O
libitum	O
.	O

All	O
experimental	O
procedures	O
were	O
approved	O
by	O
the	O
Northeast	O
Ohio	O
Medical	O
University	O
Institutional	O
Animal	O
Care	O
and	O
Use	O
Committee	O
.	O
Fig	O
.	O
1Coverage	O
of	O
cholera	B-GP
toxin	I-GP
-	I-GP
B	I-GP
(	O
CTB	B-GP
)	O
transport	O
in	O
the	O
superior	O
colliculus	O
(	O
SC	O
).	O
a	O
–	O
c	O
Whole	O
mount	O
brain	O
(	O
cortex	O
removed	O
)	O
of	O
three	O
mice	B-OG
demonstrating	O
varying	O
degrees	O
of	O
anterograde	O
transport	O
to	O
major	O
retinal	O
targets	O
that	O
include	O
lateral	O
geniculate	O
nucleus	O
(	O
LGN	O
),	O
pretectum	O
(	O
PT	O
),	O
and	O
SC	O
.	O
a	O
Colliculi	O
taken	O
from	O
a	O
12	O
-	O
month	O
-	O
old	O
D2G	O
control	O
mouse	B-OG
show	O
intact	O
axonal	O
transport	O
with	O
full	O
CTB	B-GP
coverage	O
in	O
both	O
right	O
and	O
left	O
SC	O
.	O
b	O
Colliculi	O
taken	O
from	O
a	O
14	O
-	O
month	O
-	O
old	O
DBA	B-OG
/	I-OG
2J	I-OG
mouse	I-OG
show	O
compromised	O
transport	O
;	O
left	O
SC	O
has	O
56	O
%	O
CTB	B-GP
coverage	O
,	O
right	O
SC	O
has	O
18	O
%	O
CTB	B-GP
coverage	O
.	O
c	O
Colliculi	O
taken	O
from	O
12	O
-	O
month	O
-	O
old	O
DBA	B-OG
/	I-OG
2J	I-OG
mouse	I-OG
demonstrate	O
both	O
complete	O
CTB	B-GP
dropout	O
(	O
left	O
SC	O
,	O
0	O
%	O
CTB	B-GP
)	O
and	O
complete	O
CTB	B-GP
coverage	O
(	O
right	O
SC	O
,	O
100	O
%	O
CTB	B-GP
).	O
Dotted	O
lines	O
indicate	O
delineation	O
used	O
for	O
microdissections	O
of	O
CTB	B-GP
-	O
negative	O
(	O
i	O
.	O
e	O
.,	O
transport	O
absent	O
)	O
areas	O
.	O
d	O
,	O
e	O
Whole	O
mount	O
retinas	O
with	O
successful	O
CTB	B-GP
uptake	O
via	O
intravitreal	O
injection	O
.	O
f	O
Whole	O
mount	O
SC	O
with	O
areas	O
of	O
transport	O
loss	O
,	O
corresponding	O
to	O
retinas	O
in	O
d	O
and	O
e	O
.	O

Retinal	O
images	O
(	O
d	O
,	O
e	O
)	O
provide	O
evidence	O
that	O
lack	O
of	O
CTB	B-GP
in	O
SC	O
is	O
not	O
indicative	O
of	O
failed	O
intravitreal	O
injection	O
or	O
lack	O
of	O
CTB	B-GP
uptake	O

Intravitreal	O
injection	O
of	O
CTB	B-GP

Animals	B-OG
were	O
anesthetized	O
with	O
2	O
.	O
5	O
%	O
isoflurane	O
and	O
placed	O
prone	O
in	O
a	O
stereotaxic	O
device	O
(	O
Stoelting	O
,	O
Wood	O
Dale	O
,	O
IL	O
).	O

Cholera	B-GP
toxin	I-GP
B	I-GP
-	O
subunit	O
conjugated	O
to	O
Alexa	O
Fluor	O
488	O
(	O
CTB	B-GP
)	O
was	O
injected	O
into	O
both	O
eyes	O
intravitreally	O
(	O
1	O
.	O
5	O
μl	O
of	O
0	O
.	O
1	O
%	O
CTB	B-GP
in	O
sterile	O
phosphate	O
-	O
buffered	O
saline	O
(	O
PBS	O
)	O
per	O
eye	O
;	O
Life	O
Technologies	O
:	O
Grand	O
Island	O
,	O
NY	O
)	O
using	O
a	O
33	O
-	O
gauge	O
needle	O
attached	O
to	O
a	O
25	O
μl	O
Hamilton	O
syringe	O
.	O

Forty	O
-	O
eight	O
hours	O
later	O
,	O
animals	B-OG
were	O
sacrificed	O
by	O
decapitation	O
under	O
2	O
.	O
5	O
%	O
isoflurane	O
anesthesia	O
.	O

Microdissection	O
and	O
tissue	O
collection	O

Retina	O
,	O
ONs	O
,	O
SC	O
,	O
and	O
cerebellum	O
(	O
as	O
a	O
non	O
-	O
glaucomatous	O
control	O
tissue	O
)	O
were	O
collected	O
and	O
immediately	O
frozen	O
on	O
dry	O
ice	O
.	O

Whole	O
blood	O
samples	O
were	O
collected	O
in	O
tubes	O
containing	O
500	O
mM	O
EDTA	O
on	O
wet	O
ice	O
.	O

ONs	O
were	O
bisected	O
for	O
analysis	O
of	O
the	O
proximal	O
portion	O
(	O
pON	O
)	O
and	O
distal	O
portion	O
(	O
dON	O
)	O
separately	O
.	O

Whole	O
-	O
mount	O
SC	O
were	O
imaged	O
using	O
a	O
Zeiss	O
AxioZoom	O
V16	O
epifluorescent	O
microscope	O
equipped	O
with	O
a	O
digital	O
high	O
-	O
resolution	O
camera	O
(	O
AxioCam	O
MRm	O
Rev	O
.	O
3	O
;	O
Zeiss	O
,	O
Jena	O
,	O
Germany	O
).	O

Under	O
×	O
16	O
.	O
2	O
magnification	O
,	O
SC	O
were	O
microdissected	O
into	O
“	O
transport	O
intact	O
”	O
(	O
i	O
.	O
e	O
.,	O
“	O
CTB	B-GP
-	O
positive	O
”)	O
and	O
“	O
transport	O
absent	O
”	O
(	O
i	O
.	O
e	O
.,	O
“	O
CTB	B-GP
-	O
negative	O
”)	O
samples	O
which	O
were	O
analyzed	O
separately	O
in	O
order	O
to	O
parse	O
the	O
relationship	O
between	O
transport	O
outcome	O
and	O
protein	O
levels	O
(	O
Fig	O
.	O
1	O
).	O

Retinas	O
were	O
flattened	O
and	O
examined	O
to	O
determine	O
success	O
of	O
the	O
tracer	O
injection	O
.	O

Whole	O
blood	O
samples	O
were	O
centrifuged	O
at	O
2000	O
×	O
g	O
for	O
10	O
min	O
at	O
4	O
°	O
C	O
.	O

Supernatants	O
were	O
collected	O
and	O
centrifuged	O
for	O
10	O
min	O
at	O
10	O
,	O
000	O
×	O
g	O
and	O
4	O
°	O
C	O
.	O

Final	O
supernatant	O
was	O
used	O
for	O
serum	O
analyses	O
as	O
a	O
control	O
for	O
global	O
changes	O
in	O
inflammatory	O
markers	O
.	O

Samples	O
were	O
stored	O
at	O
−	O
80	O
°	O
C	O
until	O
use	O
.	O

Tissue	O
processing	O
and	O
multiplex	O
procedure	O

Tissue	O
samples	O
were	O
rinsed	O
with	O
cold	O
PBS	O
to	O
remove	O
residual	O
blood	O
.	O

Samples	O
were	O
homogenized	O
via	O
sonication	O
(	O
10	O
%	O
amplitude	O
for	O
two	O
2	O
-	O
s	O
pulses	O
)	O
approximately	O
200	O
μl	O
of	O
0	O
.	O
1	O
%	O
Igepal	O
Ca	O
-	O
630	O
detergent	O
dissolved	O
in	O
PBS	O
with	O
protease	B-GP
inhibitor	O
cocktail	O
(	O
1	O
×	O
Halt	O
Cocktail	O
;	O
Thermo	O
Fisher	O
,	O
Waltham	O
,	O
MA	O
,	O
USA	O
)	O
and	O
centrifuged	O
at	O
1000	O
×	O
g	O
for	O
10	O
min	O
after	O
which	O
supernatants	O
were	O
collected	O
for	O
further	O
analyses	O
.	O

We	O
obtained	O
150	O
–	O
230	O
μg	O
of	O
protein	O
from	O
each	O
half	O
of	O
the	O
optic	O
nerve	O
and	O
greater	O
than	O
500	O
μg	O
protein	O
each	O
from	O
the	O
retina	O
and	O
SC	O
samples	O
.	O

These	O
amounts	O
were	O
sufficient	O
to	O
perform	O
our	O
bead	O
-	O
based	O
multiplex	O
assays	O
,	O
so	O
samples	O
were	O
not	O
pooled	O
.	O

Multiplex	O
assays	O
were	O
conducted	O
in	O
flat	O
-	O
bottom	O
96	O
-	O
well	O
plates	O
according	O
to	O
manufacturer	O
’	O
s	O
instructions	O
using	O
reagents	O
provided	O
with	O
the	O
kit	O
(	O
Invitrogen	O
Mouse	B-OG
20	O
-	O
plex	O
Cytokine	B-GP
Panel	O
,	O
Cat	O
#	O
LMC0006M	O
;	O
Life	O
Technologies	O
:	O
Grand	O
Island	O
NY	O
,	O
USA	O
).	O

In	O
brief	O
,	O
50	O
μl	O
of	O
antibody	B-GP
-	O
coupled	O
bead	O
solution	O
was	O
pipetted	O
into	O
each	O
well	O
.	O

Samples	O
were	O
diluted	O
1	O
:	O
4	O
in	O
assay	O
diluent	O
to	O
a	O
total	O
volume	O
of	O
100	O
μl	O
.	O

One	O
hundred	O
microliters	O
of	O
reconstituted	O
standard	O
was	O
serially	O
diluted	O
(	O
1	O
:	O
3	O
)	O
and	O
added	O
to	O
appropriate	O
wells	O
.	O

Fifty	O
microliters	O
of	O
Igepal	O
buffer	O
diluted	O
in	O
50	O
μl	O
assay	O
buffer	O
was	O
used	O
as	O
a	O
blank	O
.	O

Finally	O
,	O
50	O
μl	O
of	O
incubation	O
buffer	O
was	O
added	O
to	O
all	O
wells	O
.	O

Plates	O
were	O
kept	O
light	O
-	O
protected	O
during	O
an	O
overnight	O
incubation	O
(	O
4	O
°	O
C	O
,	O
16	O
–	O
18	O
h	O
)	O
on	O
a	O
titer	O
plate	O
shaker	O
at	O
600	O
rpm	O
.	O

Following	O
sample	O
incubation	O
,	O
plates	O
were	O
washed	O
with	O
a	O
mild	O
detergent	O
solution	O
using	O
a	O
magnetic	O
96	O
-	O
well	O
separator	O
three	O
times	O
(	O
1	O
min	O
per	O
wash	O
).	O

One	O
hundred	O
microliters	O
of	O
horseradish	B-OG
peroxidase	B-GP
-	O
conjugated	O
detection	O
antibody	B-GP
was	O
added	O
to	O
each	O
well	O
and	O
incubated	O
at	O
RT	O
for	O
1	O
h	O
(	O
shaking	O
at	O
600	O
rpm	O
).	O

Plates	O
were	O
washed	O
three	O
times	O
and	O
100	O
μl	O
of	O
streptavidin	B-GP
-	O
rpe	B-GP
was	O
added	O
to	O
each	O
well	O
.	O

After	O
the	O
30	O
-	O
min	O
streptavidin	B-GP
-	O
rpe	B-GP
incubation	O
,	O
plates	O
were	O
again	O
washed	O
three	O
times	O
followed	O
by	O
a	O
final	O
addition	O
of	O
125	O
μl	O
wash	O
solution	O
to	O
all	O
wells	O
.	O

After	O
3	O
min	O
of	O
vigorous	O
shaking	O
,	O
plates	O
were	O
read	O
on	O
a	O
Luminex	O
Magpix	O
unit	O
(	O
Life	O
Technologies	O
,	O
Grand	O
Island	O
,	O
NY	O
,	O
USA	O
)	O
and	O
initial	O
analyses	O
were	O
performed	O
by	O
Xponent	O
software	O
.	O

Results	O
were	O
exported	O
into	O
Microsoft	O
Excel	O
for	O
further	O
processing	O
.	O

Sample	O
size	O
was	O
set	O
to	O
50	O
μl	O
,	O
and	O
minimum	O
count	O
was	O
set	O
to	O
100	O
events	O
/	O
bead	O
region	O
.	O

Bicinchoninic	O
acid	O
assays	O
for	O
total	O
protein	O
concentration	O

An	O
aliquot	O
of	O
each	O
tissue	O
homogenate	O
was	O
diluted	O
1	O
:	O
10	O
in	O
phosphate	O
buffer	O
,	O
and	O
total	O
protein	O
content	O
was	O
assessed	O
in	O
tissue	O
samples	O
using	O
bicinchoninic	O
acid	O
(	O
BCA	O
)	O
assay	O
,	O
following	O
manufacturer	O
’	O
s	O
instructions	O
(	O
Cat	O
#	O
23225	O
,	O
Thermo	O
Fisher	O
,	O
Waltham	O
,	O
MA	O
,	O
USA	O
).	O

Cytokine	B-GP
levels	O
were	O
all	O
normalized	O
to	O
total	O
protein	O
concentration	O
by	O
dividing	O
cytokine	B-GP
concentration	O
(	O
pg	O
/	O
ml	O
)	O
by	O
total	O
protein	O
(	O
μg	O
/	O
ml	O
)	O
within	O
each	O
tissue	O
extract	O
.	O

Samples	O
were	O
not	O
pooled	O
.	O

FGF	B-GP
-	I-GP
2	I-GP
immunofluorescence	O
and	O
microscopy	O

Whole	O
mount	O
retina	O
and	O
retinal	O
cross	O
sections	O
from	O
representative	O
animals	B-OG
in	O
each	O
age	O
group	O
,	O
traced	O
with	O
CTB	B-GP
,	O
were	O
assayed	O
for	O
fibroblast	B-GP
growth	I-GP
factor	I-GP
(	B-GP
FGF	I-GP
)-	I-GP
2	I-GP
localization	O
.	O

Since	O
FGF	B-GP
-	I-GP
2	I-GP
is	O
present	O
at	O
higher	O
levels	O
than	O
most	O
other	O
cytokines	B-GP
,	O
and	O
it	O
showed	O
specific	O
differences	O
between	O
groups	O
in	O
multiplex	O
analyses	O
,	O
it	O
was	O
chosen	O
for	O
immunostaining	O
to	O
determine	O
if	O
multiplex	O
differences	O
could	O
be	O
supported	O
by	O
histology	O
.	O

Tissue	O
was	O
collected	O
from	O
animals	B-OG
given	O
a	O
lethal	O
dose	O
of	O
sodium	O
pentobarbital	O
(	O
120	O
mg	O
/	O
kg	O
,	O
ip	O
.)	O
and	O
transcardially	O
perfused	O
with	O
4	O
%	O
paraformaldehyde	O
.	O

The	O
eyes	O
were	O
enucleated	O
and	O
postfixed	O
for	O
2	O
h	O
,	O
and	O
then	O
the	O
tissue	O
was	O
placed	O
in	O
a	O
20	O
%	O
sucrose	O
cryoprotectant	O
solution	O
(%	O
w	O
/	O
v	O
in	O
PBS	O
)	O
prior	O
to	O
dissection	O
.	O

Retina	O
designated	O
for	O
cross	O
-	O
sectioning	O
were	O
embedded	O
in	O
gelatin	O
,	O
and	O
10	O
-	O
μm	O
sections	O
were	O
taken	O
on	O
a	O
cryostat	O
.	O

Whole	O
retina	O
were	O
assayed	O
as	O
free	O
-	O
floating	O
sections	O
while	O
cross	O
sections	O
were	O
assayed	O
on	O
slide	O
.	O

The	O
tissues	O
were	O
blocked	O
with	O
a	O
5	O
%	O
normal	O
donkey	B-OG
serum	O
and	O
1	O
%	O
Triton	O
-	O
X	O
100	O
in	O
PBS	O
for	O
2	O
h	O
.	O

Then	O
,	O
the	O
tissues	O
were	O
incubated	O
for	O
48	O
h	O
at	O
4	O
°	O
C	O
in	O
the	O
following	O
primary	O
antibody	B-GP
cocktail	O
(	O
diluted	O
in	O
3	O
%	O
serum	O
,	O
1	O
%	O
Triton	O
in	O
PBS	O
):	O
rabbit	B-OG
polyclonal	O
anti	O
-	O
FGF	B-GP
-	I-GP
2	I-GP
(	O
1	O
:	O
200	O
,	O
Santa	O
Cruz	O
,	O
SC	O
-	O
7911	O
;	O
Dallas	O
,	O
TX	O
)	O
and	O
mouse	B-OG
monoclonal	O
anti	O
-	O
GFAP	B-GP
(	O
1	O
:	O
500	O
,	O
Millipore	O
,	O
MAB360	O
;	O
Billerica	O
,	O
MA	O
).	O

Following	O
three	O
10	O
-	O
min	O
washes	O
with	O
PBS	O
,	O
secondary	O
antibody	B-GP
cocktail	O
was	O
added	O
for	O
2	O
h	O
at	O
room	O
temperature	O
,	O
which	O
contained	O
donkey	B-OG
anti	O
-	O
rabbit	B-OG
Alexafluor	O
594	O
(	O
1	O
:	O
250	O
,	O
Jackson	O
Laboratories	O
,	O
711	O
-	O
586	O
-	O
152	O
;	O
West	O
Grove	O
,	O
PA	O
)	O
and	O
donkey	B-OG
anti	O
-	O
mouse	B-OG
Alexafluor	O
647	O
(	O
1	O
:	O
250	O
,	O
Invitrogen	O
,	O
A	O
-	O
31571	O
;	O
Grand	O
Island	O
,	O
NY	O
).	O

The	O
tissue	O
was	O
then	O
rinsed	O
three	O
times	O
with	O
PBS	O
and	O
mounted	O
and	O
coverslipped	O
with	O
Fluoromount	O
-	O
G	O
(	O
Southern	O
Biotech	O
,	O
Birmingham	O
,	O
AL	O
).	O

Retinas	O
were	O
photographed	O
with	O
a	O
Zeiss	O
Axio	O
Imager	O
M2	O
epifluorescent	O
microscope	O
equipped	O
with	O
a	O
digital	O
high	O
-	O
resolution	O
camera	O
(	O
AxioCam	O
MRm	O
Rev	O
.	O
3	O
;	O
Zeiss	O
,	O
Jena	O
Germany	O
)	O
and	O
a	O
computer	O
-	O
guided	O
motorized	O
X	O
-	O
Y	O
stage	O
.	O

An	O
apotome	O
module	O
(	O
Zeiss	O
Apotome	O
.	O
2	O
)	O
was	O
used	O
to	O
collect	O
z	O
-	O
stack	O
of	O
images	O
using	O
structured	O
illumination	O
.	O

Statistical	O
analyses	O

Data	O
from	O
XPonent	O
and	O
Excel	O
were	O
imported	O
into	O
IBM	O
SPSS	O
for	O
Windows	O
22	O
.	O
0	O
(	O
IBM	O
Corp	O
.,	O
Armonk	O
,	O
NY	O
,	O
USA	O
)	O
for	O
statistical	O
analysis	O
.	O

Multicolinearity	O
between	O
variables	O
was	O
observed	O
,	O
necessitating	O
the	O
use	O
of	O
univariate	O
analyses	O
.	O

In	O
order	O
to	O
compare	O
relationships	O
between	O
the	O
different	O
cytokines	B-GP
and	O
minimize	O
the	O
skewed	O
distributions	O
,	O
a	O
log10	O
(	O
x	O
+	O
1	O
)	O
transformation	O
was	O
used	O
to	O
normalize	O
data	O
.	O

Results	O
are	O
reported	O
as	O
mean	O
log	O
(	O
cytokine	B-GP
concentration	O
+	O
1	O
)	O
±	O
SEM	O
.	O

The	O
log10	O
(	O
x	O
+	O
1	O
)	O
was	O
chosen	O
to	O
minimize	O
negative	O
skewedness	O
that	O
would	O
arise	O
due	O
to	O
values	O
between	O
0	O
and	O
1	O
[	O
29	O
].	O

Except	O
in	O
the	O
case	O
of	O
distal	O
optic	O
nerve	O
,	O
few	O
differences	O
between	O
cytokine	B-GP
levels	O
in	O
young	O
and	O
old	O
control	O
D2G	O
mice	B-OG
were	O
observed	O
by	O
two	O
-	O
tailed	O
,	O
independent	O
samples	O
t	O
tests	O
.	O

Therefore	O
,	O
to	O
simplify	O
analysis	O
and	O
result	O
presentation	O
,	O
data	O
from	O
these	O
mice	B-OG
were	O
combined	O
into	O
one	O
D2G	O
control	O
group	O
.	O

In	O
cases	O
where	O
age	O
-	O
dependent	O
effects	O
were	O
indicated	O
for	O
young	O
and	O
old	O
D2G	O
controls	O
,	O
these	O
data	O
are	O
either	O
shown	O
graphically	O
or	O
noted	O
within	O
the	O
results	O
.	O

One	O
-	O
way	O
analyses	O
of	O
variance	O
(	O
ANOVAs	O
)	O
were	O
used	O
to	O
test	O
for	O
differences	O
in	O
cytokine	B-GP
levels	O
among	O
groups	O
of	O
mice	B-OG
categorized	O
by	O
age	O
and	O
strain	O
[	O
D2G	O
,	O
D3	O
–	O
5	O
,	O
D8	O
–	O
10	O
,	O
D12	O
–	O
15	O
].	O

Tukey	O
’	O
s	O
honestly	O
significant	O
difference	O
(	O
HSD	O
)	O
post	O
hoc	O
measures	O
were	O
used	O
to	O
identify	O
specific	O
differences	O
between	O
age	O
and	O
strain	O
groups	O
.	O

Separate	O
analyses	O
were	O
performed	O
for	O
each	O
brain	O
structure	O
(	O
retina	O
,	O
pON	O
,	O
dON	O
,	O
SC	O
,	O
cerebellum	O
)	O
and	O
serum	O
.	O

Due	O
to	O
multiple	O
differences	O
observed	O
in	O
dON	O
between	O
G3	O
–	O
5	O
and	O
G12	O
–	O
15	O
mice	B-OG
via	O
t	O
tests	O
,	O
subsequent	O
post	O
hoc	O
comparisons	O
separated	O
G3	O
–	O
5	O
and	O
G12	O
–	O
15	O
groups	O
for	O
analysis	O
.	O

Cytokines	B-GP
included	O
in	O
analyses	O
were	O
FGF	B-GP
-	I-GP
2	I-GP
,	O
interleukin	B-GP
-	I-GP
1β	I-GP
(	O
IL	B-GP
-	I-GP
1β	I-GP
),	O
interleukin	B-GP
-	I-GP
1α	I-GP
(	O
IL	B-GP
-	I-GP
1α	I-GP
),	O
interleukin	B-GP
-	I-GP
10	I-GP
(	O
IL	B-GP
-	I-GP
10	I-GP
),	O
interleukin	B-GP
-	I-GP
13	I-GP
(	O
IL	B-GP
-	I-GP
13	I-GP
),	O
interleukin	B-GP
-	I-GP
6	I-GP
(	O
IL	B-GP
-	I-GP
6	I-GP
),	O
interleukin	B-GP
-	I-GP
12	I-GP
(	O
IL	B-GP
-	I-GP
12	I-GP
),	O
interleukin	B-GP
(	O
IL	B-GP
-	I-GP
17	I-GP
),	O
macrophage	B-GP
inflammatory	I-GP
protein	I-GP
-	I-GP
1α	I-GP
(	O
MIP	B-GP
-	I-GP
1α	I-GP
),	O
interleukin	B-GP
-	I-GP
5	I-GP
(	O
IL	B-GP
-	I-GP
5	I-GP
),	O
vascular	B-GP
endothelial	I-GP
growth	I-GP
factor	I-GP
(	O
VEGF	B-GP
),	O
tumor	B-GP
necrosis	I-GP
factor	I-GP
-	I-GP
α	I-GP
(	O
TNF	B-GP
-	I-GP
α	I-GP
),	O
interleukin	B-GP
-	I-GP
2	I-GP
(	O
IL	B-GP
-	I-GP
2	I-GP
),	O
interleukin	B-GP
-	I-GP
4	I-GP
(	O
IL	B-GP
-	I-GP
4	I-GP
),	O
monokine	B-GP
induced	I-GP
by	I-GP
interferon	I-GP
-	I-GP
γ	I-GP
(	O
MIG	B-GP
),	O
monocyte	B-GP
chemoattractant	I-GP
protein	I-GP
-	I-GP
1	I-GP
(	O
MCP	B-GP
-	I-GP
1	I-GP
),	O
keratinocyte	B-GP
chemoattractant	I-GP
(	O
KC	B-GP
),	O
and	O
interferon	B-GP
-	I-GP
γ	I-GP
(	O
IFN	B-GP
-	I-GP
γ	I-GP
).	O

For	O
subdivisions	O
of	O
SC	O
based	O
on	O
transport	O
outcome	O
,	O
ANOVAs	O
were	O
run	O
comparing	O
“	O
CTB	B-GP
-	O
positive	O
”	O
and	O
“	O
CTB	B-GP
-	O
negative	O
”	O
tissue	O
for	O
the	O
relevant	O
age	O
/	O
strain	O
groups	O
(	O
as	O
anticipated	O
,	O
D3	O
-	O
5	O
and	O
D2G	O
animals	B-OG
did	O
not	O
have	O
CTB	B-GP
-	O
negative	O
variables	O
due	O
to	O
intact	O
transport	O
).	O

For	O
purposes	O
of	O
clarity	O
,	O
graphical	O
representations	O
usually	O
include	O
only	O
those	O
cytokines	B-GP
that	O
showed	O
significant	O
differences	O
between	O
groups	O
.	O

GM	B-GP
-	I-GP
CSF	I-GP
and	O
IP	B-GP
-	I-GP
10	I-GP
were	O
eliminated	O
from	O
statistical	O
analyses	O
due	O
to	O
inconsistent	O
values	O
within	O
and	O
between	O
groups	O
and	O
low	O
number	O
of	O
structures	O
registering	O
readable	O
levels	O
of	O
these	O
cytokines	B-GP
.	O

Pearson	O
product	O
-	O
moment	O
correlation	O
coefficients	O
were	O
computed	O
to	O
assess	O
the	O
relationship	O
between	O
individual	O
cytokine	B-GP
levels	O
in	O
the	O
retina	O
and	O
SC	O
for	O
each	O
strain	O
and	O
age	O
.	O

Alpha	O
for	O
all	O
tests	O
was	O
set	O
at	O
0	O
.	O
05	O
.	O

Results	O

Early	O
elevations	O
in	O
cytokine	B-GP
levels	O
within	O
the	O
DBA	O
/	O
2J	O
retina	O

We	O
found	O
significantly	O
elevated	O
anti	O
-	O
inflammatory	O
FGF	B-GP
-	I-GP
2	I-GP
in	O
8	O
–	O
10	O
-	O
month	O
DBA	O
/	O
2J	O
retinas	O
compared	O
to	O
D2G	O
controls	O
(	O
F3	O
,	O
38	O
=	O
6	O
.	O
937	O
,	O
p	O
<	O
0	O
.	O
001	O
),	O
with	O
a	O
trend	O
towards	O
increased	O
FGF	B-GP
-	I-GP
2	I-GP
in	O
the	O
D12	O
–	O
15	O
group	O
(	O
p	O
=	O
0	O
.	O
08	O
).	O

Anti	B-GP
-	I-GP
inflammatory	I-GP
cytokines	I-GP
IL	B-GP
-	I-GP
5	I-GP
(	O
F3	O
,	O
39	O
=	O
5	O
.	O
686	O
,	O
p	O
=	O
0	O
.	O
003	O
)	O
and	O
IL	B-GP
-	I-GP
10	I-GP
(	O
F3	O
,	O
25	O
=	O
5	O
.	O
526	O
,	O
p	O
=	O
0	O
.	O
006	O
)	O
were	O
also	O
elevated	O
in	O
the	O
retina	O
of	O
D8	O
–	O
10	O
mice	B-OG
compared	O
to	O
controls	O
.	O

The	O
following	O
pro	B-GP
-	I-GP
inflammatory	I-GP
cytokines	I-GP
were	O
elevated	O
early	O
in	O
D3	O
–	O
5	O
mouse	B-OG
retina	O
compared	O
to	O
controls	O
:	O
VEGF	B-GP
(	O
F3	O
,	O
39	O
=	O
3	O
.	O
098	O
,	O
p	O
=	O
0	O
.	O
039	O
),	O
IL	B-GP
-	I-GP
12	I-GP
(	O
F3	O
,	O
39	O
=	O
3	O
.	O
982	O
,	O
p	O
=	O
0	O
.	O
015	O
),	O
IL	B-GP
-	I-GP
17	I-GP
(	O
F3	O
,	O
39	O
=	O
3	O
.	O
693	O
,	O
p	O
=	O
0	O
.	O
020	O
),	O
IL	B-GP
-	I-GP
1α	I-GP
(	O
F3	O
,	O
36	O
=	O
2	O
.	O
924	O
,	O
p	O
=	O
0	O
.	O
048	O
),	O
TNF	B-GP
-	I-GP
α	I-GP
(	O
F3	O
,	O
38	O
=	O
3	O
.	O
051	O
,	O
p	O
=	O
0	O
.	O
041	O
),	O
IFN	B-GP
-	I-GP
γ	I-GP
(	O
F3	O
,	O
37	O
=	O
3	O
.	O
904	O
,	O
p	O
=	O
0	O
.	O
017	O
),	O
MIG	B-GP
(	O
F3	O
,	O
39	O
=	O
3	O
.	O
453	O
,	O
p	O
=	O
0	O
.	O
030	O
),	O
MIP	B-GP
-	I-GP
1α	I-GP
(	O
F3	O
,	O
30	O
=	O
3	O
.	O
255	O
,	O
p	O
=	O
0	O
.	O
032	O
),	O
and	O
KC	B-GP
(	O
F3	O
,	O
39	O
=	O
6	O
.	O
311	O
,	O
p	O
=	O
0	O
.	O
009	O
).	O

KC	B-GP
also	O
remained	O
elevated	O
in	O
the	O
D8	O
-	O
10	O
retina	O
(	O
p	O
=	O
0	O
.	O
005	O
)	O
prior	O
to	O
an	O
age	O
-	O
dependent	O
decrease	O
also	O
observed	O
in	O
other	O
cytokines	B-GP
(	O
see	O
Fig	O
.	O
2	O
).	O

Additionally	O
,	O
the	O
following	O
pro	B-GP
-	I-GP
inflammatory	I-GP
cytokines	I-GP
peaked	O
at	O
8	O
–	O
10	O
months	O
of	O
age	O
in	O
DBA	O
/	O
2J	O
retinas	O
,	O
reaching	O
levels	O
that	O
were	O
significantly	O
greater	O
than	O
D2G	O
controls	O
:	O
VEGF	B-GP
(	O
F3	O
,	O
39	O
=	O
3	O
.	O
098	O
,	O
p	O
=	O
0	O
.	O
032	O
),	O
IL	B-GP
-	I-GP
17	I-GP
(	O
F3	O
,	O
39	O
=	O
3	O
.	O
693	O
,	O
p	O
=	O
0	O
.	O
034	O
),	O
IL	B-GP
-	I-GP
1α	I-GP
(	O
F3	O
,	O
36	O
=	O
2	O
.	O
924	O
,	O
p	O
=	O
0	O
.	O
029	O
),	O
TNF	B-GP
-	I-GP
α	I-GP
(	O
F3	O
,	O
38	O
=	O
3	O
.	O
051	O
,	O
p	O
=	O
0	O
.	O
029	O
),	O
and	O
IFN	B-GP
-	I-GP
γ	I-GP
(	O
F3	O
,	O
37	O
=	O
3	O
.	O
904	O
,	O
p	O
=	O
0	O
.	O
033	O
).	O
Fig	O
.	O
2Cytokine	O
protein	O
levels	O
in	O
retina	O
.	O

Anti	O
-	O
inflammatory	O
mediators	O
(	O
FGF	B-GP
-	I-GP
2	I-GP
,	O
IL	B-GP
-	I-GP
10	I-GP
,	O
and	O
IL	B-GP
-	I-GP
5	I-GP
)	O
were	O
elevated	O
in	O
8	O
–	O
10	O
-	O
month	O
DBA	B-OG
/	I-OG
2J	I-OG
mice	I-OG
and	O
often	O
demonstrated	O
an	O
age	O
-	O
dependent	O
decrease	O
(	O
a	O
).	O

A	O
number	O
of	O
pro	O
-	O
inflammatory	O
mediators	O
,	O
such	O
as	O
TNF	B-GP
-	I-GP
α	I-GP
,	O
were	O
also	O
elevated	O
in	O
D8	O
–	O
10	O
mice	B-OG
;	O
others	O
,	O
such	O
as	O
IL	B-GP
-	I-GP
12	I-GP
and	O
MIP	B-GP
-	I-GP
1α	I-GP
,	O
were	O
elevated	O
in	O
D3	O
–	O
5	O
,	O
often	O
demonstrating	O
an	O
age	O
-	O
dependent	O
decrease	O
.	O
Error	O
bars	O
depict	O
standard	O
error	O
of	O
the	O
mean	O
.	O
Asterisk	O
indicates	O
that	O
the	O
group	O
has	O
significantly	O
greater	O
levels	O
than	O
bracketed	O
comparison	O
(	O
p	O
<	O
0	O
.	O
05	O
).	O
b	O
Photomicrographs	O
depicting	O
CTB	B-GP
(	O
first	O
column	O
)	O
and	O
elevated	O
immunostaining	O
for	O
FGF	B-GP
-	I-GP
2	I-GP
(	O
second	O
column	O
)	O
and	O
GFAP	B-GP
(	O
third	O
column	O
)	O
in	O
representative	O
DBA	O
/	O
2J	O
retina	O
whole	O
mount	O
compared	O
to	O
a	O
D2G	O
.	O

Merged	O
images	O
for	O
all	O
stains	O
are	O
shown	O
in	O
the	O
fourth	O
column	O
.	O
c	O
Photomicrographs	O
of	O
elevated	O
FGF	B-GP
-	I-GP
2	I-GP
immunostaining	O
in	O
retinal	O
cross	O
sections	O
of	O
representative	O
DBA	O
/	O
2J	O
compared	O
to	O
D2G	O
.	O

Scale	O
bar	O
=	O
50	O
μm	O

No	O
significant	O
differences	O
between	O
old	O
and	O
young	O
D2G	O
retina	O
were	O
shown	O
for	O
the	O
following	O
cytokines	B-GP
:	O
FGF	B-GP
-	I-GP
2	I-GP
(	O
t	O
(	O
9	O
)	O
=	O
−	O
2	O
.	O
173	O
,	O
p	O
=	O
0	O
.	O
058	O
),	O
IL	B-GP
-	I-GP
10	I-GP
(	O
t	O
(	O
6	O
)	O
=	O
0	O
.	O
389	O
,	O
p	O
=	O
0	O
.	O
711	O
),	O
IL	B-GP
-	I-GP
5	I-GP
(	O
t	O
(	O
10	O
)	O
=	O
−	O
0	O
.	O
166	O
,	O
p	O
=	O
0	O
.	O
871	O
),	O
VEGF	B-GP
(	O
t	O
(	O
10	O
)	O
=	O
0	O
.	O
339	O
,	O
p	O
=	O
0	O
.	O
742	O
),	O
IL	B-GP
-	I-GP
12	I-GP
(	O
t	O
(	O
10	O
)	O
=	O
1	O
.	O
000	O
,	O
p	O
=	O
0	O
.	O
341	O
),	O
IL	B-GP
-	I-GP
17	I-GP
(	O
t	O
(	O
10	O
)	O
=	O
1	O
.	O
213	O
,	O
p	O
=	O
0	O
.	O
92	O
),	O
IL	B-GP
-	I-GP
1α	I-GP
(	O
t	O
(	O
10	O
)	O
=	O
0	O
.	O
552	O
,	O
p	O
=	O
0	O
.	O
593	O
),	O
TNF	B-GP
-	I-GP
α	I-GP
(	O
t	O
(	O
10	O
)	O
=	O
−	O
0	O
.	O
411	O
,	O
p	O
=	O
0	O
.	O
690	O
),	O
IFN	B-GP
-	I-GP
γ	I-GP
(	O
t	O
(	O
9	O
)	O
=	O
−	O
0	O
.	O
333	O
,	O
p	O
=	O
0	O
.	O
747	O
),	O
MIG	B-GP
(	O
t	O
(	O
10	O
)	O
=	O
−	O
0	O
.	O
385	O
,	O
p	O
=	O
0	O
.	O
708	O
),	O
MIP	B-GP
-	I-GP
1α	I-GP
(	O
t	O
(	O
10	O
)	O
=	O
1	O
.	O
206	O
,	O
p	O
=	O
0	O
.	O
255	O
),	O
and	O
KC	B-GP
(	O
t	O
(	O
10	O
)	O
=	O
−	O
0	O
.	O
957	O
,	O
p	O
=	O
0	O
.	O
361	O
)	O
(	O
data	O
not	O
shown	O
).	O

Select	O
pro	B-GP
-	I-GP
inflammatory	I-GP
cytokines	I-GP
are	O
elevated	O
in	O
pON	O
of	O
DBA	B-OG
/	I-OG
2J	I-OG
mice	I-OG

Unlike	O
the	O
retina	O
,	O
where	O
cytokines	B-GP
often	O
reached	O
peak	O
values	O
at	O
D3	O
–	O
5	O
or	O
D8	O
–	O
10	O
age	O
groups	O
,	O
cytokines	B-GP
showed	O
a	O
number	O
of	O
different	O
responses	O
in	O
pON	O
of	O
DBA	B-OG
/	I-OG
2J	I-OG
mice	I-OG
(	O
Fig	O
.	O
3	O
).	O

The	O
levels	O
of	O
the	O
anti	O
-	O
inflammatory	O
modulator	O
,	O
FGF	B-GP
-	I-GP
2	I-GP
,	O
were	O
significantly	O
lower	O
in	O
pON	O
of	O
D3	O
–	O
5	O
mice	B-OG
compared	O
to	O
all	O
other	O
groups	O
(	O
F3	O
,	O
36	O
=	O
6	O
.	O
577	O
,	O
p	O
<	O
0	O
.	O
05	O
).	O
Fig	O
.	O
3Cytokine	O
protein	O
levels	O
in	O
proximal	O
optic	O
nerve	O
(	O
pON	O
).	O

Anti	O
-	O
inflammatory	O
FGF	B-GP
-	I-GP
2	I-GP
and	O
pro	O
-	O
inflammatory	O
IL	B-GP
-	I-GP
6	I-GP
and	O
MIP	B-GP
-	I-GP
1α	I-GP
levels	O
were	O
lower	O
in	O
the	O
pON	O
of	O
young	O
DBA	B-OG
/	I-OG
2J	I-OG
mice	I-OG
than	O
all	O
other	O
groups	O
.	O

Pro	O
-	O
inflammatory	O
IL	B-GP
-	I-GP
12	I-GP
was	O
only	O
elevated	O
in	O
pON	O
of	O
young	O
and	O
middle	O
-	O
aged	O
DBA	B-OG
/	I-OG
2J	I-OG
mice	I-OG
.	O
Asterisk	O
indicates	O
that	O
D3	O
–	O
5	O
mice	B-OG
have	O
significantly	O
lower	O
cytokine	B-GP
levels	O
than	O
D2G	O
controls	O
and	O
D8	O
–	O
10	O
and	O
D12	O
–	O
15	O
pON	O
.	O
Number	O
sign	O
indicates	O
significance	O
greater	O
than	O
bracketed	O
comparison	O
(	O
p	O
<	O
0	O
.	O
05	O
).	O
Arrows	O
indicate	O
values	O
below	O
limits	O
of	O
detection	O
for	O
the	O
assay	O
.	O
Error	O
bars	O
depict	O
standard	O
error	O
of	O
the	O
mean	O

While	O
the	O
pro	B-GP
-	I-GP
inflammatory	I-GP
cytokine	I-GP
,	O
MIP	B-GP
-	I-GP
1α	I-GP
,	O
was	O
significantly	O
lower	O
in	O
pON	O
of	O
D3	O
–	O
5	O
mice	B-OG
compared	O
to	O
controls	O
(	O
F3	O
,	O
36	O
=	O
4	O
.	O
125	O
,	O
p	O
=	O
0	O
.	O
009	O
),	O
others	O
showed	O
elevations	O
in	O
DBA	O
/	O
2J	O
groups	O
compared	O
to	O
controls	O
.	O

Pro	O
-	O
inflammatory	O
IL	B-GP
-	I-GP
6	I-GP
was	O
elevated	O
in	O
D12	O
–	O
15	O
mice	B-OG
compared	O
to	O
controls	O
and	O
D3	O
–	O
5	O
mice	B-OG
(	O
F3	O
,	O
34	O
=	O
6	O
.	O
041	O
,	O
p	O
=	O
0	O
.	O
014	O
).	O

IL	B-GP
-	I-GP
12	I-GP
,	O
on	O
the	O
other	O
hand	O
,	O
was	O
significantly	O
elevated	O
in	O
D3	O
–	O
5	O
and	O
D8	O
–	O
10	O
mice	B-OG
compared	O
to	O
controls	O
and	O
D12	O
–	O
15	O
,	O
which	O
showed	O
little	O
to	O
no	O
IL	B-GP
-	I-GP
12	I-GP
in	O
pON	O
(	O
F3	O
,	O
28	O
=	O
3	O
.	O
682	O
,	O
p	O
=	O
0	O
.	O
026	O
).	O

Finally	O
,	O
IL	B-GP
-	I-GP
1β	I-GP
was	O
elevated	O
in	O
all	O
DBA	O
/	O
2J	O
groups	O
compared	O
to	O
controls	O
(	O
F3	O
,	O
15	O
=	O
5	O
.	O
948	O
,	O
p	O
=	O
0	O
.	O
036	O
).	O

(	O
Data	O
are	O
illustrated	O
in	O
Fig	O
.	O
3	O
).	O

No	O
significant	O
differences	O
were	O
seen	O
between	O
old	O
and	O
young	O
D2G	O
pON	O
in	O
the	O
following	O
cytokines	B-GP
:	O
FGF	B-GP
-	I-GP
2	I-GP
(	O
t	O
(	O
10	O
)	O
=	O
−	O
1	O
.	O
921	O
,	O
p	O
=	O
0	O
.	O
084	O
),	O
IL	B-GP
-	I-GP
1β	I-GP
(	O
t	O
(	O
4	O
)	O
=	O
1	O
.	O
633	O
,	O
p	O
=	O
0	O
.	O
178	O
),	O
IL	B-GP
-	I-GP
6	I-GP
(	O
t	O
(	O
9	O
)	O
=	O
0	O
.	O
003	O
,	O
p	O
=	O
0	O
.	O
998	O
),	O
IL	B-GP
-	I-GP
12	I-GP
(	O
no	O
IL	B-GP
-	I-GP
12	I-GP
was	O
detected	O
in	O
D2Gs	O
,	O
so	O
t	O
test	O
not	O
computed	O
),	O
MIP	B-GP
-	I-GP
1α	I-GP
(	O
t	O
(	O
10	O
)	O
=	O
0	O
.	O
450	O
,	O
p	O
=	O
0	O
.	O
662	O
).	O

However	O
,	O
MCP	B-GP
-	I-GP
1	I-GP
(	O
t	O
(	O
6	O
)	O
=	O
4	O
.	O
130	O
,	O
p	O
=	O
0	O
.	O
006	O
)	O
and	O
IL	B-GP
-	I-GP
5	I-GP
(	O
t	O
(	O
9	O
)	O
=	O
2	O
.	O
871	O
,	O
p	O
=	O
0	O
.	O
018	O
)	O
were	O
significantly	O
reduced	O
in	O
old	O
D2G	O
pON	O
compared	O
to	O
young	O
D2G	O
pON	O
;	O
MCP	B-GP
-	I-GP
1	I-GP
showed	O
the	O
opposite	O
trend	O
in	O
DBA	O
/	O
2J	O
pON	O
,	O
and	O
IL	B-GP
-	I-GP
5	I-GP
was	O
not	O
significantly	O
different	O
among	O
DBA	O
/	O
2J	O
pONs	O
across	O
ages	O
.	O

D2G	O
controls	O
were	O
combined	O
since	O
no	O
differences	O
were	O
shown	O
among	O
cytokines	B-GP
that	O
changed	O
significantly	O
for	O
the	O
D2	O
pON	O
(	O
data	O
not	O
shown	O
).	O

Age	O
-	O
dependent	O
effects	O
in	O
the	O
distal	O
ON	O
of	O
D2G	O
controls	O
are	O
absent	O
in	O
DBA	B-OG
/	I-OG
2J	I-OG
mice	I-OG

Few	O
significant	O
differences	O
were	O
observed	O
in	O
dON	O
among	O
DBA	O
/	O
2J	O
groups	O
(	O
Fig	O
.	O
4	O
).	O

Pro	O
-	O
inflammatory	O
IL	B-GP
-	I-GP
1β	I-GP
was	O
elevated	O
in	O
dON	O
of	O
all	O
DBA	B-OG
/	I-OG
2J	I-OG
mice	I-OG
compared	O
to	O
that	O
of	O
controls	O
(	O
F3	O
,	O
26	O
=	O
3	O
.	O
274	O
,	O
p	O
=	O
0	O
.	O
039	O
);	O
notably	O
,	O
this	O
pro	B-GP
-	I-GP
inflammatory	I-GP
cytokine	I-GP
was	O
not	O
detected	O
in	O
D2G	O
mice	B-OG
at	O
all	O
,	O
but	O
was	O
detected	O
in	O
all	O
DBA	O
/	O
2J	O
groups	O
to	O
some	O
degree	O
.	O

Also	O
,	O
pro	O
-	O
inflammatory	O
MCP	B-GP
-	I-GP
1	I-GP
was	O
significantly	O
elevated	O
in	O
D8	O
–	O
10	O
and	O
D12	O
–	O
15	O
dON	O
compared	O
to	O
controls	O
(	O
F3	O
,	O
23	O
=	O
3	O
.	O
186	O
,	O
p	O
=	O
0	O
.	O
046	O
).	O
Fig	O
.	O
4Cytokine	O
protein	O
levels	O
in	O
distal	O
optic	O
nerve	O
.	O

For	O
all	O
cytokines	B-GP
shown	O
,	O
with	O
the	O
exception	O
of	O
IL	B-GP
-	I-GP
1β	I-GP
and	O
MCP	B-GP
-	I-GP
1	I-GP
,	O
there	O
was	O
a	O
significant	O
age	O
-	O
dependent	O
increase	O
in	O
D2G	O
control	O
mice	B-OG
that	O
was	O
not	O
apparent	O
in	O
DBA	B-OG
/	I-OG
2J	I-OG
mice	I-OG
.	O

Pro	O
-	O
inflammatory	O
IL	B-GP
-	I-GP
1β	I-GP
was	O
only	O
detected	O
in	O
DBA	B-OG
/	I-OG
2J	I-OG
mice	I-OG
(	O
arrows	O
indicate	O
values	O
below	O
the	O
detection	O
limit	O
of	O
assay	O
).	O
Asterisk	O
indicates	O
that	O
the	O
group	O
has	O
significantly	O
higher	O
levels	O
than	O
bracketed	O
comparisons	O
(	O
p	O
<	O
0	O
.	O
05	O
).	O
Error	O
bars	O
show	O
the	O
standard	O
error	O
of	O
the	O
mean	O

Interestingly	O
,	O
unlike	O
other	O
tissue	O
types	O
,	O
the	O
dON	O
showed	O
a	O
variety	O
of	O
differences	O
between	O
young	O
and	O
old	O
D2G	O
mice	B-OG
.	O

Therefore	O
,	O
analyses	O
used	O
the	O
separated	O
D2G	O
groups	O
as	O
described	O
previously	O
(	O
G3	O
–	O
5	O
and	O
G12	O
–	O
14	O
),	O
along	O
with	O
D3	O
–	O
5	O
,	O
D8	O
–	O
10	O
,	O
and	O
D12	O
–	O
15	O
.	O

Pro	B-GP
-	I-GP
inflammatory	I-GP
cytokines	I-GP
and	O
growth	O
factors	O
that	O
showed	O
a	O
significant	O
elevation	O
in	O
G12	O
–	O
15	O
compared	O
to	O
G3	O
–	O
5	O
mice	B-OG
were	O
as	O
follows	O
:	O
VEGF	B-GP
(	O
t	O
(	O
10	O
)	O
=	O
4	O
.	O
025	O
,	O
p	O
=	O
0	O
.	O
002	O
),	O
MIG	B-GP
(	O
t	O
(	O
9	O
)	O
=	O
3	O
.	O
572	O
,	O
p	O
=	O
0	O
.	O
006	O
),	O
and	O
KC	B-GP
(	O
t	O
(	O
10	O
)	O
=	O
4	O
.	O
698	O
,	O
p	O
=	O
0	O
.	O
001	O
).	O

MIP	B-GP
-	I-GP
1α	I-GP
was	O
significantly	O
elevated	O
in	O
G12	O
–	O
15	O
compared	O
to	O
G3	O
–	O
5	O
and	O
all	O
DBA	O
/	O
2J	O
groups	O
(	O
F4	O
,	O
39	O
=	O
7	O
.	O
060	O
,	O
p	O
≤	O
0	O
.	O
009	O
).	O

Anti	B-GP
-	I-GP
inflammatory	I-GP
cytokines	I-GP
that	O
showed	O
an	O
age	O
-	O
dependent	O
elevation	O
between	O
G3	O
–	O
5	O
and	O
G12	O
–	O
15	O
were	O
IL	B-GP
-	I-GP
10	I-GP
(	O
t	O
(	O
6	O
)	O
=	O
5	O
.	O
831	O
,	O
p	O
=	O
0	O
.	O
001	O
)	O
and	O
IL	B-GP
-	I-GP
4	I-GP
(	O
t	O
(	O
10	O
)	O
=	O
2	O
.	O
576	O
,	O
p	O
=	O
0	O
.	O
028	O
).	O

Notably	O
,	O
G12	O
–	O
15	O
mice	B-OG
had	O
significantly	O
increased	O
anti	O
-	O
inflammatory	O
IL	B-GP
-	I-GP
10	I-GP
levels	O
compared	O
to	O
DBA	B-OG
/	I-OG
2J	I-OG
mice	I-OG
of	O
all	O
ages	O
(	O
F4	O
,	O
29	O
=	O
5	O
.	O
107	O
,	O
p	O
=	O
0	O
.	O
029	O
).	O

(	O
Data	O
are	O
illustrated	O
in	O
Fig	O
.	O
4	O
).	O

Early	O
increases	O
in	O
pro	B-GP
-	I-GP
inflammatory	I-GP
cytokine	I-GP
levels	O
in	O
the	O
DBA	O
/	O
2J	O
SC	O

Early	O
increases	O
in	O
cytokine	B-GP
levels	O
were	O
observed	O
in	O
SC	O
of	O
DBA	B-OG
/	I-OG
2J	I-OG
mice	I-OG
(	O
without	O
accounting	O
for	O
transport	O
differences	O
)	O
compared	O
to	O
D2G	O
controls	O
.	O

Anti	O
-	O
inflammatory	O
modulators	O
IL	B-GP
-	I-GP
4	I-GP
(	O
F3	O
,	O
40	O
=	O
5	O
.	O
605	O
,	O
p	O
=	O
0	O
.	O
003	O
)	O
and	O
IL	B-GP
-	I-GP
5	I-GP
(	O
F3	O
,	O
41	O
=	O
3	O
.	O
713	O
,	O
p	O
=	O
0	O
.	O
019	O
)	O
were	O
both	O
significantly	O
elevated	O
in	O
D8	O
–	O
10	O
mice	B-OG
compared	O
to	O
controls	O
.	O

Pro	O
-	O
inflammatory	O
modulators	O
,	O
IFN	B-GP
-	I-GP
γ	I-GP
(	O
F3	O
,	O
31	O
=	O
4	O
.	O
352	O
,	O
p	O
=	O
0	O
.	O
012	O
)	O
and	O
KC	B-GP
(	O
F3	O
,	O
42	O
=	O
6	O
.	O
035	O
,	O
p	O
=	O
0	O
.	O
002	O
),	O
were	O
significantly	O
increased	O
in	O
both	O
D3	O
–	O
5	O
mice	B-OG
and	O
D8	O
–	O
10	O
mice	B-OG
compared	O
to	O
D2G	O
.	O

Pro	O
-	O
inflammatory	O
IL	B-GP
-	I-GP
12	I-GP
was	O
detected	O
at	O
extremely	O
low	O
levels	O
in	O
controls	O
and	O
old	O
DBA	O
/	O
2J	O
SC	O
,	O
but	O
in	O
respect	O
to	O
these	O
values	O
was	O
increased	O
in	O
D8	O
–	O
10	O
mice	B-OG
and	O
levels	O
were	O
significantly	O
higher	O
in	O
D3	O
–	O
5	O
mice	B-OG
(	O
F3	O
,	O
37	O
=	O
5	O
.	O
021	O
,	O
p	O
=	O
0	O
.	O
005	O
).	O

(	O
Data	O
are	O
illustrated	O
in	O
Fig	O
.	O
5	O
).	O
Fig	O
.	O
5Cytokine	O
protein	O
levels	O
in	O
superior	O
colliculus	O
(	O
SC	O
).	O

Anti	O
-	O
inflammatory	O
IL	B-GP
-	I-GP
4	I-GP
and	O
IL	B-GP
-	I-GP
5	I-GP
were	O
elevated	O
in	O
D8	O
–	O
10	O
mice	B-OG
,	O
while	O
pro	O
-	O
inflammatory	O
IFN	B-GP
-	I-GP
γ	I-GP
and	O
KC	B-GP
were	O
elevated	O
in	O
D3	O
–	O
5	O
and	O
D8	O
–	O
10	O
DBA	B-OG
/	I-OG
2J	I-OG
mice	I-OG
compared	O
to	O
controls	O
.	O

Pro	O
-	O
inflammatory	O
IL	B-GP
-	I-GP
12	I-GP
levels	O
were	O
increased	O
in	O
D3	O
–	O
5	O
DBA	B-OG
/	I-OG
2J	I-OG
mice	I-OG
compared	O
to	O
controls	O
and	O
12	O
–	O
15	O
DBA	B-OG
/	I-OG
2J	I-OG
mice	I-OG
.	O
Arrows	O
indicate	O
levels	O
below	O
the	O
detection	O
limit	O
of	O
the	O
assay	O
.	O
Asterisk	O
indicates	O
that	O
the	O
group	O
has	O
significantly	O
higher	O
levels	O
than	O
bracketed	O
comparisons	O
(	O
p	O
<	O
0	O
.	O
05	O
).	O
Error	O
bars	O
indicate	O
the	O
standard	O
error	O
of	O
the	O
mean	O

There	O
were	O
no	O
significant	O
differences	O
between	O
old	O
and	O
young	O
D2G	O
SC	O
for	O
the	O
majority	O
of	O
cytokines	B-GP
,	O
including	O
those	O
illustrated	O
(	O
IL	B-GP
-	I-GP
4	I-GP
,	O
IL	B-GP
-	I-GP
5	I-GP
,	O
IL	B-GP
-	I-GP
6	I-GP
IFN	B-GP
-	I-GP
γ	I-GP
,	O
MIG	B-GP
,	O
IL	B-GP
-	I-GP
12	I-GP
,	O
and	O
KC	B-GP
).	O

However	O
,	O
pro	O
-	O
inflammatory	O
IL	B-GP
-	I-GP
17	I-GP
was	O
significantly	O
reduced	O
in	O
old	O
D2G	O
SC	O
compared	O
to	O
young	O
D2G	O
cohorts	O
(	O
t	O
(	O
10	O
)	O
=	O
3	O
.	O
820	O
,	O
p	O
=	O
0	O
.	O
003	O
;	O
data	O
not	O
shown	O
).	O

IL	B-GP
-	I-GP
6	I-GP
is	O
the	O
only	O
cytokine	B-GP
that	O
demonstrates	O
a	O
relationship	O
to	O
axonal	O
transport	O
outcome	O

Most	O
cytokines	B-GP
did	O
not	O
differ	O
based	O
on	O
anterograde	O
transport	O
outcome	O
of	O
CTB	B-GP
;	O
however	O
,	O
IL	B-GP
-	I-GP
6	I-GP
was	O
an	O
exception	O
.	O

IL	B-GP
-	I-GP
6	I-GP
levels	O
were	O
significantly	O
increased	O
in	O
transport	O
-	O
absent	O
SC	O
compared	O
to	O
transport	O
-	O
intact	O
SC	O
(	O
F5	O
,	O
31	O
=	O
5	O
.	O
543	O
,	O
p	O
=	O
0	O
.	O
001	O
;	O
Fig	O
.	O
6	O
).	O

This	O
finding	O
is	O
of	O
particular	O
interest	O
because	O
elevation	O
of	O
IL	B-GP
-	I-GP
6	I-GP
was	O
not	O
apparent	O
when	O
analyzing	O
the	O
SC	O
data	O
before	O
segregation	O
of	O
samples	O
based	O
on	O
transport	O
outcome	O
.	O
Fig	O
.	O
6IL	O
-	O
6	O
levels	O
based	O
on	O
age	O
,	O
strain	O
,	O
and	O
CTB	B-GP
transport	O
to	O
the	O
superior	O
colliculus	O
(	O
SC	O
).	O

Differences	O
in	O
collicular	O
IL	B-GP
-	I-GP
6	I-GP
levels	O
emerged	O
in	O
12	O
–	O
15	O
-	O
month	O
-	O
old	O
mice	B-OG
based	O
on	O
transport	O
outcome	O
,	O
with	O
transport	O
absent	O
regions	O
(	O
CTB	B-GP
−)	O
demonstrating	O
significantly	O
greater	O
IL	B-GP
-	I-GP
6	I-GP
than	O
transport	O
intact	O
(	O
CTB	B-GP
+)	O
regions	O
(	O
asterisk	O
indicates	O
p	O
<	O
0	O
.	O
05	O
).	O

There	O
is	O
no	O
anticipated	O
loss	O
of	O
transport	O
in	O
controls	O
and	O
D3	O
–	O
5	O
-	O
month	O
-	O
old	O
groups	O
.	O
Error	O
bars	O
show	O
standard	O
error	O
of	O
the	O
mean	O

Cerebellum	O

No	O
significant	O
differences	O
in	O
cerebellar	O
cytokine	B-GP
levels	O
were	O
observed	O
in	O
DBA	O
/	O
2J	O
and	O
D2G	O
mice	B-OG
across	O
ages	O
(	O
Table	O
2	O
)	O
indicating	O
that	O
differences	O
in	O
cytokine	B-GP
levels	O
are	O
not	O
generalizable	O
to	O
the	O
nervous	O
system	O
in	O
these	O
mice	B-OG
.	O
Table	O
1Summary	O
of	O
group	O
nomenclature	O
and	O
N	O
valuesStrainAgeGroup	O
nomenclatureMice	O
per	O
group	O
(	O
N	O
)	O
Projections	O
analyzed	O
(	O
n	O
)	O
D2G3	O
–	O
5	O
monthsD2Ga	O
48D2G12	O
–	O
15	O
months46DBA	O
/	O
2J3	O
–	O
5	O
monthsD3	O
–	O
5510DBA	O
/	O
2J8	O
–	O
10	O
monthsD8	O
–	O
10612DBA	O
/	O
2J12	O
–	O
15	O
monthsD12	O
–	O
15510	O
aYoung	O
and	O
old	O
D2G	O
mice	B-OG
were	O
combined	O
into	O
a	O
single	O
control	O
group	O
in	O
order	O
to	O
simplify	O
results	O
when	O
possible	O
;	O
independent	O
samples	O
t	O
tests	O
indicated	O
that	O
young	O
and	O
old	O
D2G	O
mice	B-OG
showed	O
few	O
differences	O
in	O
their	O
cytokines	B-GP
levels	O
.	O

When	O
detected	O
,	O
differences	O
were	O
described	O
within	O
the	O
results	O
section	O
using	O
G3	O
–	O
5	O
and	O
G12	O
–	O
15	O
(	O
referring	O
to	O
young	O
and	O
old	O
D2G	O
mice	B-OG
,	O
respectively	O
)	O
Table	O
2Cerebellar	O
cytokine	B-GP
levels	O
across	O
age	O
and	O
strainG3	O
–	O
5G12	O
–	O
15D3	O
–	O
5D8	O
–	O
10D12	O
–	O
15Mean	O
(	O
pg	O
/	O
mg	O
protein	O
)±	O
SEMMean	O
(	O
pg	O
/	O
mg	O
protein	O
)±	O
SEMMean	O
(	O
pg	O
/	O
mg	O
protein	O
)±	O
SEMMean	O
(	O
pg	O
/	O
mg	O
protein	O
)±	O
SEMMean	O
(	O
pg	O
/	O
mg	O
protein	O
)±	O
SEMFGF	B-GP
-	I-GP
2574	I-GP
.	O
4020	O
.	O
60562	O
.	O
7030	O
.	O
40452	O
.	O
6012	O
.	O
30473	O
.	O
30122	O
.	O
50531	O
.	O
3057	O
.	O
20IFN	B-GP
-	I-GP
γ2	I-GP
.	O
200	O
.	O
902	O
.	O
001	O
.	O
001	O
.	O
800	O
.	O
906	O
.	O
302	O
.	O
902	O
.	O
201	O
.	O
80IL	B-GP
-	I-GP
1α2	I-GP
.	O
500	O
.	O
301	O
.	O
200	O
.	O
301	O
.	O
800	O
.	O
904	O
.	O
401	O
.	O
802	O
.	O
901	O
.	O
60IL	B-GP
-	I-GP
1β2	I-GP
.	O
600	O
.	O
8016	O
.	O
8012	O
.	O
507	O
.	O
206	O
.	O
207	O
.	O
103	O
.	O
909	O
.	O
605	O
.	O
20IL	B-GP
-	I-GP
22	I-GP
.	O
300	O
.	O
602	O
.	O
500	O
.	O
301	O
.	O
100	O
.	O
604	O
.	O
402	O
.	O
903	O
.	O
101	O
.	O
70IL	B-GP
-	I-GP
46	I-GP
.	O
775	O
.	O
9027	O
.	O
500	O
.	O
1021	O
.	O
5014	O
.	O
003	O
.	O
000	O
.	O
0023	O
.	O
8020	O
.	O
90IL	B-GP
-	I-GP
51	I-GP
.	O
660	O
.	O
681	O
.	O
800	O
.	O
563	O
.	O
600	O
.	O
914	O
.	O
562	O
.	O
103	O
.	O
011	O
.	O
17IL	O
-	O
69	O
.	O
801	O
.	O
808	O
.	O
700	O
.	O
305	O
.	O
100	O
.	O
8010	O
.	O
604	O
.	O
508	O
.	O
703	O
.	O
40IL	B-GP
-	I-GP
101	I-GP
.	O
600	O
.	O
2014	O
.	O
603	O
.	O
808	O
.	O
206	O
.	O
0030	O
.	O
1027	O
.	O
9026	O
.	O
8023	O
.	O
70IL	B-GP
-	I-GP
133	I-GP
.	O
103	O
.	O
107	O
.	O
907	O
.	O
902	O
.	O
600	O
.	O
9012	O
.	O
607	O
.	O
309	O
.	O
875	O
.	O
00IL	O
-	O
12	O
––––	O
3	O
.	O
301	O
.	O
900	O
.	O
900	O
.	O
90	O
––	O
IL	B-GP
-	I-GP
170	I-GP
.	O
200	O
.	O
030	O
.	O
040	O
.	O
020	O
.	O
040	O
.	O
010	O
.	O
300	O
.	O
100	O
.	O
200	O
.	O
09KC215	O
.	O
5532	O
.	O
7699	O
.	O
2567	O
.	O
50133	O
.	O
0763	O
.	O
85268	O
.	O
0666	O
.	O
14199	O
.	O
6760	O
.	O
04MCP	B-GP
-	I-GP
1N	I-GP
/	O
AN	O
/	O
A	O
––––	O
1	O
.	O
901	O
.	O
901	O
.	O
350	O
.	O
69MIG86	B-GP
.	O
9619	O
.	O
4810	O
.	O
402	O
.	O
4011	O
.	O
732	O
.	O
7212	O
.	O
984	O
.	O
8612	O
.	O
094	O
.	O
64MIP	B-GP
-	I-GP
1α10	I-GP
.	O
100	O
.	O
307	O
.	O
800	O
.	O
109	O
.	O
180	O
.	O
6014	O
.	O
435	O
.	O
2010	O
.	O
302	O
.	O
95TNF	O
-	O
α0	O
.	O
720	O
.	O
721	O
.	O
200	O
.	O
4611	O
.	O
706	O
.	O
351	O
.	O
481	O
.	O
481	O
.	O
721	O
.	O
72En	O
dashes	O
indicate	O
that	O
all	O
values	O
were	O
below	O
the	O
limit	O
of	O
detection	O
;	O
for	O
such	O
cases	O
,	O
a	O
zero	O
was	O
recorded	O
.	O

N	O
/	O
A	O
indicates	O
that	O
the	O
majority	O
of	O
samples	O
had	O
no	O
reading	O
or	O
an	O
error	O
reading	O
,	O
which	O
is	O
distinguished	O
from	O
a	O
reading	O
that	O
is	O
simply	O
below	O
the	O
limit	O
of	O
detection	O

Serum	O

There	O
were	O
no	O
differences	O
between	O
DBA	O
/	O
2J	O
and	O
D2G	O
serum	O
levels	O
of	O
cytokines	B-GP
,	O
indicating	O
that	O
changes	O
observed	O
in	O
visual	O
system	O
tissues	O
were	O
not	O
globally	O
present	O
.	O

Cytokine	B-GP
measurements	O
in	O
serum	O
showed	O
much	O
higher	O
inter	O
-	O
sample	O
variability	O
than	O
cytokine	B-GP
levels	O
in	O
the	O
other	O
tissue	O
analyzed	O
in	O
this	O
study	O
.	O

Relationship	O
between	O
retina	O
and	O
SC	O
cytokine	B-GP
levels	O

Given	O
the	O
frequent	O
disconnect	O
between	O
pathology	O
in	O
the	O
retina	O
versus	O
targets	O
in	O
the	O
brain	O
,	O
we	O
sought	O
to	O
identify	O
any	O
relationships	O
in	O
cytokine	B-GP
levels	O
between	O
these	O
two	O
structures	O
.	O

Few	O
cytokines	B-GP
showed	O
a	O
strong	O
and	O
consistent	O
relationship	O
between	O
retinal	O
and	O
collicular	O
levels	O
(	O
p	O
>	O
0	O
.	O
05	O
).	O

However	O
,	O
FGF	B-GP
-	I-GP
2	I-GP
levels	O
in	O
the	O
retina	O
and	O
SC	O
were	O
significantly	O
correlated	O
in	O
our	O
youngest	O
D2G	O
and	O
DBA	B-OG
/	I-OG
2J	I-OG
mice	I-OG
[	O
Fig	O
.	O
7	O
,	O
G3	O
–	O
5	O
(	O
r2	O
=	O
0	O
.	O
887	O
,	O
p	O
=	O
0	O
.	O
018	O
);	O
D3	O
–	O
5	O
(	O
r2	O
=	O
0	O
.	O
849	O
,	O
p	O
=	O
0	O
.	O
016	O
)].	O

This	O
relationship	O
was	O
not	O
reflected	O
in	O
older	O
animals	B-OG
of	O
either	O
strain	O
.	O

This	O
finding	O
suggests	O
that	O
age	O
,	O
independent	O
of	O
pathology	O
,	O
may	O
disrupt	O
the	O
association	O
between	O
retinal	O
and	O
collicular	O
FGF	B-GP
-	I-GP
2	I-GP
levels	O
in	O
mice	B-OG
.	O

Pathological	O
changes	O
may	O
further	O
challenge	O
this	O
relationship	O
,	O
as	O
we	O
observed	O
elevations	O
in	O
absolute	O
retinal	O
FGF	B-GP
-	I-GP
2	I-GP
levels	O
in	O
DBA	B-OG
/	I-OG
2J	I-OG
mice	I-OG
compared	O
to	O
controls	O
(	O
see	O
Fig	O
.	O
2	O
).	O
Fig	O
.	O
7Scatterplot	O
showing	O
relationship	O
between	O
retinal	O
and	O
collicular	O
FGF	B-GP
-	I-GP
2	I-GP
levels	O
.	O

Symbols	O
represent	O
individual	O
retina	O
versus	O
the	O
corresponding	O
superior	O
colliculus	O
.	O

Significant	O
positive	O
correlations	O
were	O
indicated	O
between	O
retinal	O
and	O
collicular	O
FGF	B-GP
-	I-GP
2	I-GP
levels	O
for	O
both	O
young	O
D2G	O
(	O
3	O
–	O
5	O
months	O
)	O
and	O
young	O
DBA	O
/	O
2J	O
(	O
3	O
–	O
5	O
months	O
)	O
mice	B-OG
(	O
Pearson	O
’	O
s	O
r	O
2	O
).	O
Regression	O
lines	O
have	O
been	O
drawn	O
for	O
each	O
of	O
these	O
groups	O
to	O
illustrate	O
these	O
relationships	O
.	O

No	O
significant	O
relationships	O
were	O
shown	O
for	O
other	O
groups	O
,	O
including	O
aged	O
D2G	O
mice	B-OG
.	O
p	O
values	O
are	O
indicated	O
on	O
the	O
figure	O

Additionally	O
,	O
IL	B-GP
-	I-GP
6	I-GP
retinal	O
and	O
collicular	O
levels	O
in	O
young	O
D2G	O
mice	B-OG
were	O
positively	O
correlated	O
,	O
and	O
there	O
was	O
a	O
trend	O
towards	O
this	O
effect	O
in	O
the	O
oldest	O
D2G	O
mice	B-OG
[	O
G3	O
–	O
5	O
(	O
r2	O
=	O
0	O
.	O
961	O
,	O
p	O
=	O
0	O
.	O
009	O
);	O
G12	O
–	O
15	O
(	O
r2	O
=	O
0	O
.	O
736	O
,	O
p	O
=	O
0	O
.	O
08	O
)].	O

No	O
such	O
relationships	O
between	O
retinal	O
and	O
collicular	O
IL	B-GP
-	I-GP
6	I-GP
levels	O
were	O
shown	O
in	O
any	O
DBA	O
/	O
2J	O
group	O
(	O
Fig	O
.	O
8	O
).	O

The	O
absence	O
of	O
this	O
relationship	O
in	O
DBA	B-OG
/	I-OG
2J	I-OG
mice	I-OG
at	O
any	O
age	O
indicates	O
that	O
there	O
may	O
be	O
an	O
early	O
and	O
sustained	O
disruption	O
in	O
the	O
association	O
of	O
retinal	O
and	O
collicular	O
IL	B-GP
-	I-GP
6	I-GP
.	O
Fig	O
.	O
8Scatterplot	O
showing	O
relationship	O
between	O
retinal	O
and	O
collicular	O
IL	B-GP
-	I-GP
6	I-GP
.	O
Symbols	O
represent	O
individual	O
retina	O
versus	O
the	O
corresponding	O
superior	O
colliculus	O
.	O

A	O
significant	O
,	O
positive	O
correlation	O
between	O
retinal	O
and	O
collicular	O
IL	B-GP
-	I-GP
6	I-GP
levels	O
in	O
young	O
D2G	O
mice	B-OG
(	O
Pearson	O
’	O
s	O
r	O
2	O
)	O
and	O
a	O
strong	O
trend	O
towards	O
this	O
same	O
relationship	O
was	O
indicated	O
in	O
old	O
D2G	O
mice	B-OG
.	O
Regression	O
lines	O
have	O
been	O
drawn	O
for	O
each	O
of	O
these	O
groups	O
to	O
illustrate	O
relationships	O
.	O

No	O
significant	O
relationships	O
were	O
shown	O
for	O
other	O
groups	O
.	O
p	O
values	O
are	O
indicated	O
on	O
figure	O

FGF	B-GP
-	I-GP
2	I-GP
immunofluorescence	O

Cross	O
sectioned	O
and	O
whole	O
retina	O
show	O
a	O
clear	O
distinction	O
in	O
FGF	B-GP
-	I-GP
2	I-GP
levels	O
between	O
D2G	O
and	O
DBA	O
/	O
2J	O
groups	O
,	O
with	O
all	O
DBA	O
/	O
2J	O
groups	O
demonstrating	O
increased	O
FGF	B-GP
-	I-GP
2	I-GP
immunoreactivity	O
(	O
Fig	O
.	O
2	O
),	O
which	O
supports	O
multiplex	O
data	O
from	O
the	O
retina	O
.	O

The	O
distinction	O
between	O
DBA	O
/	O
2J	O
groups	O
illustrated	O
by	O
multiplex	O
analyses	O
,	O
however	O
,	O
is	O
not	O
as	O
apparent	O
in	O
histological	O
sections	O
.	O

Inner	O
and	O
outer	O
plexiform	O
layers	O
are	O
most	O
densely	O
stained	O
for	O
FGF	B-GP
-	I-GP
2	I-GP
,	O
with	O
diffuse	O
staining	O
throughout	O
other	O
layers	O
of	O
the	O
retina	O
.	O

Data	O
illustrates	O
that	O
the	O
retinal	O
ganglion	O
cell	O
layer	O
is	O
not	O
the	O
only	O
location	O
of	O
FGF	B-GP
-	I-GP
2	I-GP
,	O
and	O
therefore	O
,	O
the	O
FGF	B-GP
-	I-GP
2	I-GP
detected	O
by	O
multiplex	O
analyses	O
is	O
mostly	O
due	O
to	O
its	O
concentration	O
in	O
these	O
other	O
layers	O
.	O

This	O
also	O
suggests	O
that	O
glia	O
and	O
other	O
cell	O
types	O
constitute	O
the	O
majority	O
of	O
FGF	B-GP
-	I-GP
2	I-GP
production	O
in	O
the	O
retina	O
.	O

Müller	O
glia	O
are	O
likely	O
a	O
major	O
producer	O
of	O
FGF	B-GP
-	I-GP
2	I-GP
as	O
reported	O
by	O
Hageman	O
and	O
colleagues	O
[	O
30	O
]	O
and	O
others	O
(	O
refer	O
to	O
[	O
31	O
,	O
32	O
]).	O

Discussion	O

Glaucoma	B-DS
is	O
an	O
age	B-DS
-	I-DS
related	I-DS
degenerative	I-DS
disorder	I-DS
in	O
which	O
microglial	O
abnormalities	O
have	O
been	O
described	O
,	O
especially	O
at	O
the	O
optic	O
nerve	O
head	O
and	O
retina	O
[	O
18	O
,	O
33	O
].	O

Specifically	O
,	O
microglia	O
are	O
found	O
in	O
activated	O
,	O
ramified	O
clusters	O
within	O
the	O
glaucomatous	O
optic	O
nerve	O
head	O
[	O
33	O
].	O

However	O
,	O
despite	O
the	O
initial	O
changes	O
to	O
ONH	O
,	O
we	O
have	O
previously	O
reported	O
that	O
pathology	O
,	O
presumably	O
due	O
to	O
these	O
changes	O
,	O
manifests	O
distally	O
in	O
retinal	O
targets	O
such	O
as	O
SC	O
[	O
4	O
].	O

This	O
disparity	O
between	O
locations	O
of	O
the	O
stressor	O
and	O
manifestation	O
of	O
pathology	O
is	O
commonly	O
seen	O
in	O
neurodegenerative	B-DS
disorders	I-DS
[	O
34	O
].	O

Despite	O
this	O
pattern	O
of	O
progression	O
,	O
a	O
comprehensive	O
description	O
of	O
cytokine	B-GP
profiles	O
throughout	O
this	O
projection	O
apart	O
from	O
retina	O
and	O
optic	O
nerve	O
head	O
has	O
not	O
been	O
done	O
.	O

Our	O
work	O
provides	O
an	O
age	O
-	O
dependent	O
analysis	O
of	O
cytokine	B-GP
levels	O
throughout	O
the	O
entire	O
retinal	O
projection	O
of	O
the	O
glaucomatous	O
DBA	O
/	O
2J	O
model	O
with	O
respect	O
to	O
functional	O
outcome	O
.	O

Cytokine	B-GP
protein	O
levels	O
along	O
RGC	O
projection	O
with	O
age	O
and	O
pathology	O

Early	O
elevations	O
of	O
classically	O
categorized	O
pro	B-GP
-	I-GP
inflammatory	I-GP
cytokines	I-GP
—	O
specifically	O
IFNγ	B-GP
,	O
MIG	B-GP
,	O
KC	B-GP
,	O
TNF	B-GP
-	I-GP
α	I-GP
,	O
and	O
MIP	B-GP
-	I-GP
1α	I-GP
—	O
observed	O
in	O
the	O
retina	O
and	O
SC	O
may	O
signal	O
the	O
progression	O
of	O
pathological	O
changes	O
in	O
the	O
visual	O
projection	O
of	O
DBA	B-OG
/	I-OG
2J	I-OG
mice	I-OG
prior	O
to	O
functional	O
transport	O
loss	O
and	O
RGC	O
death	O
.	O

While	O
the	O
majority	O
of	O
changes	O
we	O
observed	O
were	O
in	O
pro	O
-	O
inflammatory	O
mediators	O
,	O
our	O
results	O
suggest	O
that	O
anti	B-GP
-	I-GP
inflammatory	I-GP
cytokines	I-GP
may	O
play	O
a	O
compensatory	O
role	O
early	O
in	O
glaucoma	B-DS
prior	O
to	O
transport	O
loss	O
,	O
as	O
evidenced	O
by	O
early	O
elevations	O
in	O
retinal	O
IL	B-GP
-	I-GP
5	I-GP
and	O
IL	B-GP
-	I-GP
10	I-GP
.	O

Other	O
work	O
has	O
shown	O
that	O
IL	B-GP
-	I-GP
10	I-GP
plays	O
a	O
role	O
in	O
RGC	O
survival	O
and	O
IL	B-GP
-	I-GP
5	I-GP
has	O
similar	O
functions	O
[	O
35	O
].	O

TNF	B-GP
-	I-GP
α	I-GP
is	O
another	O
important	O
pro	B-GP
-	I-GP
inflammatory	I-GP
cytokine	I-GP
that	O
was	O
found	O
to	O
be	O
upregulated	O
in	O
the	O
retina	O
of	O
8	O
–	O
10	O
-	O
month	O
DBA	B-OG
/	I-OG
2J	I-OG
mice	I-OG
,	O
which	O
is	O
expected	O
given	O
that	O
TNF	B-GP
-	I-GP
α	I-GP
has	O
cytotoxic	O
effects	O
associated	O
with	O
apoptotic	O
signaling	O
[	O
36	O
].	O

In	O
support	O
of	O
our	O
findings	O
,	O
recent	O
work	O
has	O
shown	O
that	O
TNF	B-GP
-	I-GP
α	I-GP
may	O
actually	O
be	O
protective	O
early	O
in	O
glaucomatous	O
pathology	O
,	O
as	O
TNF	B-GP
-	I-GP
α	I-GP
expression	O
is	O
upregulated	O
immediately	O
following	O
nerve	O
crush	O
and	O
TNF	B-GP
-	I-GP
α	I-GP
deficiency	O
intensifies	O
RGC	O
injury	O
following	O
nerve	O
crush	O
[	O
19	O
].	O

Previous	O
work	O
from	O
other	O
laboratories	O
has	O
shown	O
increased	O
immunolabeling	O
of	O
TNF	B-GP
-	I-GP
α	I-GP
and	O
its	O
associated	O
death	B-GP
receptor	I-GP
,	O
TNF	B-GP
-	I-GP
R1	I-GP
,	O
in	O
the	O
optic	O
nerve	O
head	O
and	O
retina	O
of	O
glaucomatous	O
human	B-OG
donor	O
eyes	O
[	O
37	O
,	O
38	O
].	O

While	O
TNF	B-GP
-	I-GP
α	I-GP
was	O
upregulated	O
primarily	O
in	O
glia	O
of	O
retina	O
and	O
optic	O
nerve	O
head	O
,	O
the	O
TNF	B-GP
-	I-GP
1R	I-GP
was	O
most	O
prominent	O
in	O
RGC	O
bodies	O
,	O
suggesting	O
that	O
RGCs	O
may	O
be	O
especially	O
susceptible	O
to	O
the	O
effects	O
of	O
TNF	B-GP
-	I-GP
α	I-GP
[	O
37	O
,	O
38	O
].	O

Conversely	O
,	O
TNF	B-GP
-	I-GP
α	I-GP
has	O
also	O
been	O
shown	O
to	O
have	O
early	O
neuroprotective	O
effects	O
via	O
actions	O
of	O
the	O
less	O
-	O
prominent	O
TNF	B-GP
-	I-GP
R2	I-GP
.	O

While	O
some	O
RGC	O
death	O
can	O
be	O
observed	O
in	O
the	O
8	O
–	O
10	O
-	O
month	O
DBA	O
/	O
2J	O
retina	O
,	O
the	O
protective	O
effects	O
associated	O
with	O
TNF	B-GP
-	I-GP
R2	I-GP
may	O
be	O
why	O
there	O
is	O
a	O
temporal	O
delay	O
between	O
observed	O
TNF	B-GP
-	I-GP
α	I-GP
elevations	O
and	O
the	O
age	O
at	O
which	O
RGC	O
death	O
becomes	O
overwhelmingly	O
significant	O
(	O
13	O
–	O
15	O
months	O
;	O
refer	O
to	O
[	O
7	O
]).	O

Additionally	O
,	O
FGF	B-GP
-	I-GP
2	I-GP
upregulation	O
was	O
shown	O
in	O
the	O
retina	O
of	O
8	O
–	O
10	O
-	O
month	O
-	O
old	O
DBA	B-OG
/	I-OG
2J	I-OG
mice	I-OG
(	O
with	O
trends	O
towards	O
this	O
elevation	O
in	O
D3	O
–	O
5	O
and	O
D12	O
–	O
15	O
groups	O
),	O
suggesting	O
that	O
FGF	B-GP
-	I-GP
2	I-GP
may	O
be	O
an	O
early	O
signal	O
of	O
cellular	O
stress	O
.	O

Recently	O
,	O
the	O
Noda	O
laboratory	O
described	O
the	O
response	O
of	O
microglia	O
to	O
FGF	B-GP
-	I-GP
2	I-GP
with	O
experiments	O
that	O
demonstrated	O
that	O
(	O
a	O
)	O
degenerating	O
neurons	O
released	O
FGF	B-GP
-	I-GP
2	I-GP
and	O
that	O
(	O
b	O
)	O
microglia	O
specifically	O
responded	O
to	O
this	O
FGF	B-GP
-	I-GP
2	I-GP
release	O
by	O
adopting	O
an	O
amoeboid	O
phenotype	O
and	O
migrating	O
towards	O
FGF	B-GP
-	I-GP
2	I-GP
at	O
sites	O
of	O
neuronal	O
degeneration	O
[	O
39	O
].	O

In	O
our	O
studies	O
,	O
FGF	B-GP
-	I-GP
2	I-GP
levels	O
in	O
retina	O
and	O
SC	O
of	O
young	O
D2G	O
mice	B-OG
were	O
similar	O
,	O
but	O
became	O
dissociated	O
in	O
older	O
D2Gs	O
.	O

This	O
age	O
-	O
dependent	O
pattern	O
of	O
FGF	B-GP
-	I-GP
2	I-GP
expression	O
in	O
the	O
retina	O
and	O
SC	O
was	O
recapitulated	O
in	O
DBA	B-OG
/	I-OG
2J	I-OG
mice	I-OG
,	O
but	O
their	O
overall	O
FGF	B-GP
-	I-GP
2	I-GP
levels	O
were	O
an	O
order	O
of	O
magnitude	O
above	O
those	O
of	O
the	O
D2G	O
controls	O
.	O

Therefore	O
,	O
while	O
FGF	B-GP
-	I-GP
2	I-GP
levels	O
may	O
become	O
deregulated	O
between	O
the	O
retina	O
and	O
SC	O
as	O
a	O
feature	O
of	O
normal	O
aging	O
,	O
it	O
is	O
likely	O
that	O
the	O
actual	O
magnitude	O
of	O
concentrations	O
and	O
not	O
the	O
relative	O
values	O
between	O
structures	O
are	O
the	O
important	O
factor	O
in	O
DBA	O
/	O
2J	O
pathology	O
.	O

Immunostaining	O
in	O
the	O
retina	O
also	O
supported	O
multiplex	O
FGF	B-GP
-	I-GP
2	I-GP
data	O
overall	O
,	O
showing	O
an	O
increase	O
in	O
the	O
DBA	O
/	O
2J	O
retina	O
compared	O
to	O
D2G	O
controls	O
.	O

It	O
is	O
noteworthy	O
that	O
FGF	B-GP
-	I-GP
2	I-GP
expression	O
was	O
apparent	O
in	O
several	O
layers	O
,	O
specifically	O
the	O
outer	O
and	O
inner	O
plexiform	O
layers	O
of	O
the	O
retina	O
and	O
not	O
just	O
in	O
ganglion	O
cells	O
;	O
this	O
is	O
relevant	O
since	O
the	O
whole	O
retina	O
was	O
analyzed	O
in	O
the	O
multiplexing	O
experiments	O
.	O

FGF	B-GP
-	I-GP
2	I-GP
is	O
produced	O
by	O
a	O
variety	O
of	O
cell	O
types	O
including	O
Müller	O
glia	O
,	O
RGCs	O
,	O
and	O
other	O
cell	O
types	O
[	O
30	O
,	O
31	O
].	O

Furthermore	O
,	O
FGF	B-GP
-	I-GP
2	I-GP
stimulates	O
Müller	O
cell	O
proliferation	O
[	O
32	O
].	O

Wen	O
and	O
colleagues	O
also	O
showed	O
that	O
FGF	B-GP
-	I-GP
2	I-GP
is	O
upregulated	O
in	O
the	O
retina	O
in	O
response	O
to	O
acute	O
,	O
mechanical	O
injury	O
and	O
suggested	O
that	O
this	O
actually	O
serves	O
as	O
a	O
protective	O
response	O
in	O
the	O
context	O
of	O
photoreceptor	B-DS
degeneration	I-DS
[	O
31	O
].	O

While	O
chronic	O
,	O
glaucomatous	O
neurodegeneration	O
differs	O
distinctly	O
from	O
this	O
acute	O
type	O
of	O
photoreceptor	B-DS
degeneration	I-DS
,	O
it	O
is	O
still	O
a	O
logical	O
extrapolation	O
that	O
our	O
observed	O
FGF	B-GP
-	I-GP
2	I-GP
elevations	O
within	O
DBA	O
/	O
2J	O
retina	O
could	O
be	O
an	O
intrinsic	O
signal	O
or	O
attempt	O
to	O
by	O
retinal	O
cells	O
to	O
be	O
“	O
rescued	O
.”	O

While	O
FGF	B-GP
-	I-GP
2	I-GP
elevations	O
and	O
other	O
anti	O
-	O
inflammatory	O
changes	O
in	O
the	O
SC	O
did	O
differ	O
significantly	O
between	O
DBA	O
/	O
2J	O
age	O
groups	O
,	O
anti	O
-	O
inflammatory	O
IL	B-GP
-	I-GP
4	I-GP
and	O
IL	B-GP
-	I-GP
5	I-GP
were	O
elevated	O
in	O
the	O
D8	O
–	O
10	O
age	O
group	O
.	O

Additionally	O
,	O
a	O
number	O
of	O
pro	B-GP
-	I-GP
inflammatory	I-GP
cytokines	I-GP
were	O
elevated	O
in	O
young	O
DBA	B-OG
/	I-OG
2J	I-OG
mice	I-OG
compared	O
to	O
D2G	O
mice	B-OG
and	O
older	O
DBA	B-OG
/	I-OG
2J	I-OG
mice	I-OG
.	O

For	O
example	O
,	O
KC	B-GP
was	O
elevated	O
in	O
all	O
D3	O
–	O
5	O
and	O
D8	O
–	O
10	O
groups	O
compared	O
to	O
D2G	O
mice	B-OG
,	O
which	O
may	O
drive	O
some	O
of	O
the	O
more	O
prolonged	O
inflammation	O
and	O
advanced	O
pathology	O
within	O
the	O
DBA	O
/	O
2J	O
strain	O
.	O

This	O
idea	O
is	O
supported	O
by	O
data	O
in	O
htau	B-GP
mice	B-OG
,	O
a	O
common	O
neurodegenerative	O
model	O
for	O
Alzheimer	B-DS
’	I-DS
s	I-DS
disease	I-DS
,	O
which	O
show	O
elevated	O
KC	B-GP
and	O
MIG	B-GP
,	O
among	O
other	O
pro	O
-	O
inflammatory	O
mediators	O
,	O
within	O
their	O
cortex	O
when	O
compared	O
to	O
controls	O
[	O
40	O
].	O

Other	O
pro	B-GP
-	I-GP
inflammatory	I-GP
cytokines	I-GP
elevated	O
in	O
D3	O
–	O
5	O
SC	O
included	O
IL	B-GP
-	I-GP
12	I-GP
and	O
IFN	B-GP
-	I-GP
γ	I-GP
,	O
which	O
may	O
also	O
perpetuate	O
early	O
pathology	O
prior	O
to	O
transport	O
loss	O
.	O

Interestingly	O
,	O
distal	O
portions	O
of	O
the	O
ON	O
in	O
control	O
mice	B-OG
showed	O
age	O
-	O
dependent	O
elevations	O
in	O
cytokines	B-GP
—	O
a	O
finding	O
that	O
was	O
absent	O
in	O
aging	O
DBA	B-OG
/	I-OG
2J	I-OG
mice	I-OG
and	O
contrasted	O
with	O
findings	O
in	O
other	O
regions	O
of	O
the	O
visual	O
projection	O
.	O

Some	O
notable	O
changes	O
in	O
dON	O
of	O
D2G	O
mice	B-OG
with	O
age	O
were	O
in	O
levels	O
of	O
anti	B-GP
-	I-GP
inflammatory	I-GP
cytokines	I-GP
IL	B-GP
-	I-GP
10	I-GP
,	O
and	O
IL	B-GP
-	I-GP
4	I-GP
,	O
suggesting	O
that	O
these	O
may	O
be	O
protective	O
elevations	O
that	O
occur	O
in	O
the	O
distal	O
projection	O
of	O
the	O
ON	O
during	O
normal	O
aging	O
.	O

This	O
was	O
corroborated	O
by	O
the	O
finding	O
that	O
DBA	B-OG
/	I-OG
2J	I-OG
mice	I-OG
lacked	O
this	O
response	O
as	O
they	O
aged	O
.	O

Notably	O
,	O
IL	B-GP
-	I-GP
1β	I-GP
was	O
significantly	O
elevated	O
in	O
both	O
proximal	O
and	O
distal	O
portions	O
of	O
the	O
optic	O
nerve	O
in	O
DBA	B-OG
/	I-OG
2J	I-OG
mice	I-OG
compared	O
to	O
controls	O
,	O
indicating	O
a	O
possible	O
role	O
for	O
this	O
cytokine	B-GP
in	O
distal	B-DS
axonopathy	I-DS
in	O
glaucoma	B-DS
[	O
4	O
].	O

IL	B-GP
-	I-GP
1β	I-GP
has	O
been	O
shown	O
to	O
be	O
an	O
upstream	O
activator	O
of	O
JNK	B-GP
via	O
transforming	B-GP
growth	I-GP
factor	I-GP
-	I-GP
β	I-GP
activating	I-GP
kinase	I-GP
-	I-GP
1	I-GP
(	O
TAK1	B-GP
)	O
[	O
41	O
],	O
and	O
hyperphosphorylation	O
of	O
neurofilaments	O
and	O
motor	B-GP
proteins	I-GP
by	O
JNK	B-GP
may	O
alter	O
the	O
substrate	O
and	O
machinery	O
by	O
which	O
axonal	O
transport	O
occurs	O
to	O
sustain	O
cellular	O
and	O
axonal	O
viability	O
[	O
42	O
].	O

Cytokines	B-GP
and	O
axonal	O
transport	O

Largely	O
,	O
changes	O
in	O
cytokine	B-GP
levels	O
were	O
independent	O
of	O
axonal	O
transport	O
outcome	O
in	O
the	O
SC	O
as	O
well	O
as	O
in	O
the	O
corresponding	O
retina	O
.	O

However	O
,	O
due	O
to	O
the	O
small	O
sample	O
size	O
and	O
variability	O
within	O
the	O
DBA	O
/	O
2J	O
strain	O
,	O
these	O
data	O
should	O
be	O
interpreted	O
cautiously	O
.	O

Interestingly	O
,	O
IL	B-GP
-	I-GP
6	I-GP
was	O
the	O
only	O
molecule	O
that	O
differed	O
based	O
on	O
transport	O
outcome	O
;	O
as	O
expected	O
,	O
IL	B-GP
-	I-GP
6	I-GP
levels	O
were	O
highest	O
in	O
the	O
most	O
pathological	O
(	O
i	O
.	O
e	O
.,	O
transport	O
-	O
absent	O
)	O
SC	O
at	O
12	O
–	O
15	O
months	O
.	O

Given	O
that	O
RGC	O
death	O
in	O
DBA	B-OG
/	I-OG
2J	I-OG
mice	I-OG
occurs	O
most	O
significantly	O
at	O
18	O
months	O
of	O
age	O
[	O
28	O
]	O
and	O
D8	O
–	O
10	O
SC	O
showed	O
no	O
differences	O
in	O
IL	B-GP
-	I-GP
6	I-GP
based	O
on	O
transport	O
,	O
increased	O
IL	B-GP
-	I-GP
6	I-GP
in	O
transport	O
-	O
deficient	O
SC	O
of	O
D12	O
–	O
15	O
mice	B-OG
may	O
signal	O
impending	O
RGC	O
loss	O
.	O

This	O
contrasts	O
with	O
reports	O
in	O
the	O
retina	O
,	O
which	O
has	O
shown	O
that	O
an	O
IL	B-GP
-	I-GP
6	I-GP
transducer	O
was	O
elevated	O
under	O
conditions	O
of	O
glaucoma	B-DS
-	O
related	O
stress	O
before	O
RGC	O
loss	O
[	O
43	O
].	O

The	O
function	O
of	O
IL	B-GP
-	I-GP
6	I-GP
in	O
these	O
regions	O
has	O
been	O
suggested	O
to	O
be	O
involved	O
in	O
the	O
regeneration	O
of	O
injured	O
axons	O
in	O
optic	B-DS
nerve	I-DS
trauma	I-DS
and	O
more	O
acute	O
IOP	O
elevation	O
[	O
44	O
].	O

The	O
chronic	O
degeneration	O
in	O
DBA	B-OG
/	I-OG
2J	I-OG
mice	I-OG
,	O
however	O
,	O
presents	O
a	O
more	O
complicated	O
scenario	O
.	O

While	O
IL	B-GP
-	I-GP
6	I-GP
levels	O
were	O
significantly	O
reduced	O
in	O
the	O
proximal	O
optic	O
nerve	O
of	O
DBA	B-OG
/	I-OG
2J	I-OG
mice	I-OG
compared	O
to	O
controls	O
,	O
possibly	O
due	O
to	O
transport	O
deficits	O
,	O
these	O
levels	O
increased	O
with	O
age	O
and	O
were	O
significantly	O
greater	O
in	O
the	O
SC	O
of	O
the	O
oldest	O
DBA	O
/	O
2J	O
groups	O
.	O

Given	O
that	O
we	O
do	O
not	O
see	O
extensive	O
axon	O
injury	O
until	O
then	O
[	O
4	O
,	O
7	O
,	O
8	O
,	O
28	O
],	O
elevation	O
of	O
IL	B-GP
-	I-GP
6	I-GP
within	O
the	O
D12	O
-	O
15	O
SC	O
suggests	O
that	O
this	O
signaling	O
may	O
be	O
a	O
neuroprotective	O
mechanism	O
attempting	O
to	O
salvage	O
or	O
replace	O
lost	O
connections	O
[	O
44	O
].	O

We	O
observed	O
that	O
IL	B-GP
-	I-GP
6	I-GP
levels	O
were	O
highly	O
correlated	O
between	O
the	O
retina	O
and	O
SC	O
of	O
young	O
D2G	O
mice	B-OG
,	O
and	O
there	O
was	O
a	O
trend	O
toward	O
this	O
relationship	O
in	O
the	O
old	O
D2G	O
controls	O
.	O

However	O
,	O
in	O
DBA	B-OG
/	I-OG
2J	I-OG
mice	I-OG
,	O
we	O
did	O
not	O
see	O
a	O
relationship	O
between	O
retinal	O
and	O
collicular	O
IL	B-GP
-	I-GP
6	I-GP
.	O
As	O
has	O
been	O
suggested	O
previously	O
[	O
44	O
],	O
IL	B-GP
-	I-GP
6	I-GP
may	O
be	O
elevated	O
specifically	O
in	O
response	O
to	O
axon	O
damage	O
.	O

Given	O
that	O
we	O
have	O
previously	O
reported	O
distal	B-DS
axonopathy	I-DS
in	O
this	O
model	O
,	O
we	O
would	O
expect	O
elevations	O
in	O
IL	B-GP
-	I-GP
6	I-GP
to	O
occur	O
in	O
the	O
distal	O
targets	O
(	O
e	O
.	O
g	O
.,	O
SC	O
)	O
first	O
,	O
therefore	O
uncoupling	O
the	O
relationship	O
between	O
retina	O
and	O
SC	O
.	O

Conclusion	O

Dysregulation	O
of	O
cytokine	B-GP
signaling	O
throughout	O
the	O
RGC	O
projection	O
of	O
DBA	B-OG
/	I-OG
2J	I-OG
mice	I-OG
is	O
evident	O
early	O
in	O
pathology	O
.	O

Early	O
elevations	O
of	O
classic	O
pro	B-GP
-	I-GP
inflammatory	I-GP
cytokines	I-GP
in	O
the	O
retina	O
—	O
specifically	O
IFNγ	B-GP
,	O
MIG	B-GP
,	O
KC	B-GP
,	O
TNF	B-GP
-	I-GP
α	I-GP
,	O
and	O
MIP	B-GP
-	I-GP
1α	I-GP
as	O
well	O
as	O
consistent	O
elevations	O
in	O
IL	B-GP
-	I-GP
1β	I-GP
throughout	O
the	O
ON	O
may	O
signal	O
the	O
progression	O
of	O
pathological	O
changes	O
in	O
the	O
visual	O
projection	O
of	O
DBA	B-OG
/	I-OG
2J	I-OG
mice	I-OG
prior	O
to	O
functional	O
transport	O
loss	O
and	O
RGC	O
death	O
.	O

Additionally	O
,	O
differences	O
in	O
cytokine	B-GP
levels	O
,	O
either	O
age	O
-	O
related	O
or	O
strain	O
-	O
related	O
,	O
are	O
compartmentalized	O
throughout	O
the	O
RGC	O
projection	O
.	O

Overall	O
,	O
DBA	B-OG
/	I-OG
2J	I-OG
mice	I-OG
show	O
many	O
age	O
-	O
dependent	O
changes	O
in	O
pro	B-GP
-	I-GP
inflammatory	I-GP
cytokines	I-GP
and	O
some	O
alterations	O
in	O
anti	B-GP
-	I-GP
inflammatory	I-GP
cytokines	I-GP
that	O
are	O
not	O
observed	O
in	O
control	O
mice	B-OG
within	O
the	O
retina	O
and	O
proximal	O
ON	O
and	O
SC	O
.	O

Our	O
data	O
suggest	O
that	O
changes	O
in	O
cytokine	B-GP
and	O
growth	O
factor	O
levels	O
may	O
occur	O
prior	O
to	O
functional	O
transport	O
loss	O
and	O
are	O
consistent	O
with	O
previous	O
work	O
showing	O
inflammatory	O
changes	O
and	O
immune	O
-	O
mediated	O
vasoconstriction	O
early	O
in	O
glaucomatous	O
pathology	O
[	O
25	O
].	O

Such	O
alterations	O
in	O
immunomodulatory	O
molecules	O
may	O
be	O
among	O
the	O
subtle	O
changes	O
that	O
occur	O
prior	O
to	O
overt	O
cytoskeletal	O
damage	O
,	O
loss	O
of	O
axonal	O
transport	O
,	O
and	O
cell	O
death	O
.	O

However	O
,	O
IL	B-GP
-	I-GP
6	I-GP
levels	O
were	O
elevated	O
in	O
accordance	O
with	O
axonal	O
transport	O
loss	O
in	O
our	O
oldest	O
DBA	B-OG
/	I-OG
2J	I-OG
mice	I-OG
,	O
indicating	O
that	O
IL	B-GP
-	I-GP
6	I-GP
may	O
be	O
a	O
reliable	O
marker	O
of	O
late	O
pathological	O
states	O
[	O
44	O
].	O

Previous	O
work	O
by	O
Luterman	O
and	O
colleagues	O
[	O
45	O
]	O
showed	O
a	O
similar	O
pattern	O
in	O
patients	O
with	O
late	O
/	O
terminal	O
Alzheimer	B-DS
’	I-DS
s	I-DS
disease	I-DS
exhibiting	O
greater	O
amounts	O
of	O
IL	B-GP
-	I-GP
6	I-GP
mRNA	O
in	O
entorhinal	O
cortex	O
and	O
temporal	O
gyrus	O
compared	O
to	O
controls	O
.	O

This	O
group	O
also	O
demonstrated	O
that	O
levels	O
of	O
IL	B-GP
-	I-GP
6	I-GP
were	O
positively	O
correlated	O
with	O
neurofibrillary	O
tangles	O
[	O
45	O
].	O

Thus	O
,	O
IL	B-GP
-	I-GP
6	I-GP
elevations	O
in	O
the	O
SC	O
may	O
be	O
closely	O
coupled	O
to	O
structural	O
demise	O
and	O
axonal	O
loss	O
,	O
as	O
previous	O
work	O
from	O
our	O
lab	O
has	O
shown	O
that	O
both	O
retrograde	O
transport	O
deficits	O
and	O
structural	O
loss	O
are	O
characteristic	O
of	O
the	O
12	O
–	O
15	O
-	O
month	O
DBA	O
/	O
2J	O
group	O
[	O
7	O
].	O

However	O
,	O
the	O
current	O
study	O
did	O
not	O
directly	O
assess	O
this	O
relationship	O
.	O

Given	O
that	O
our	O
findings	O
indicate	O
a	O
complex	O
role	O
for	O
cytokine	B-GP
signaling	O
throughout	O
the	O
RGC	O
projection	O
,	O
it	O
would	O
be	O
interesting	O
to	O
parse	O
out	O
immune	O
cell	O
phenotypes	O
responsible	O
for	O
cytokine	B-GP
release	O
versus	O
resting	O
,	O
phagocytotic	O
,	O
primed	O
,	O
or	O
senescent	O
phenotypes	O
throughout	O
the	O
projection	O
as	O
a	O
function	O
of	O
strain	O
and	O
age	O
.	O

Additionally	O
,	O
further	O
investigation	O
into	O
the	O
interplay	O
between	O
the	O
immune	O
system	O
and	O
axonal	O
transport	O
disruption	O
via	O
downstream	O
,	O
kinase	B-GP
-	O
mediated	O
cytoskeletal	O
,	O
or	O
motor	B-GP
protein	I-GP
modifications	O
could	O
also	O
provide	O
important	O
insight	O
into	O
the	O
progression	O
and	O
potential	O
therapeutic	O
targets	O
of	O
glaucoma	B-DS
and	O
other	O
related	O
neurodegenerations	O
.	O

Competing	O
interests	O

The	O
authors	O
declare	O
that	O
they	O
have	O
no	O
competing	O
interests	O
.	O

